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Runt-related transcription factor 1 (RUNX1) is a transcription factor that has an important role 
in haematopoietic cell development and function and is frequently disrupted in leukaemia. 
RUNX1 is commonly described as a sequence-specific DNA binding factor which recognises the 
consensus sequence TG(T/C)GGT in the promoter and enhancer regions of its target genes to 
affect changes in gene expression. However, the advent of techniques to study DNA-protein 
interactions on a genome-wide scale has provided the opportunity to re-assess RUNX1 
localisation and function, and this analysis suggests that the classical model of RUNX1 function 
is incomplete. By fully understanding the mechanisms by which RUNX1 maintains its target 
gene expression profiles under normal cellular conditions, insights into disrupted function can 
be gained and interventions can be developed. 
 
Analysis of publicly available RUNX1 ChIP-Seq data determined that the majority of RUNX1 
binding in haematopoietic cells occurs outside of gene promoter regions, in intergenic or 
intronic regions. Furthermore, approximately one fifth of all RUNX1-DNA binding sites on a 
genome-wide scale were not associated with a canonical consensus sequence, and this was 
particularly prevalent in promoter regions, with almost half of RUNX1 binding in promoter 
regions occurring in the absence of consensus sequences. This suggests that recruitment of 
RUNX1 to gene targets occurs through multiple mechanisms and raises the possibility that it 
may function differently depending on its location and mode of recruitment. Similar results 
were obtained for localisation of the RUNX1 fusion protein RUNX1-ETO, the product of a 
common chromosomal translocation in leukaemia.  
 
This data set was used to investigate the different modes of binding and action of RUNX1 with 
the aim of establishing whether binding in the absence of consensus sequences constitutes a 
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novel mechanism of RUNX1 binding and if genes regulated in this way respond differently to 
RUNX1 disruption. This study identified biological pathways enriched for genes with RUNX1 
binding in their promoters, and in which only one type of binding (in the presence or absence 
of a consensus sequence) occurred. Clusters of functionally related RUNX1-bound genes were 
selected from two of these pathways; the RhoA and HMGB1 signalling pathways and used as 
models to investigate regulation by RUNX1. 
 
The RhoA signalling pathway genes, ARHGAP1, ARHGAP4 and ARHGAP12, all bound RUNX1 at 
their promoters, in association with a consensus sequence. However, while ARHGAP4 and 
ARHGAP12 responded to RUNX1 in reporter assays, ARHGAP1 did not, suggesting that a 
consensus sequence alone is not sufficient for a promoter to respond to RUNX1. In contrast, a 
group of histone acetyl transferase genes from the HMGB1 signalling pathway bound RUNX1 
at their promoters in the absence of a consensus sequence. Both the KAT6B and KAT2B 
promoters were activated by RUNX1 in the absence of a consensus sequence, suggesting a 
mechanism whereby RUNX1 recruitment to DNA does not require the canonical consequence 
sequence and may rely on recruitment by additional transcription factors or distal chromatin 
elements. Interestingly, evidence presented here indicates that while RUNX1-ETO inhibits 
RUNX1 activity at classically regulated promoters which contain RUNX consensus sequences, it 
cannot inhibit RUNX1 activity in the absence of canonical consensus sequences.  This suggests 
that genes regulated by RUNX1 through different transcriptional mechanisms may respond 
differently to disruption of RUNX1 in diseases such as leukaemia.  
 
The majority of RUNX1 binding occurs outside of promoters, with one potential explanation for 
intergenic or intronic RUNX1 binding being that it functions at gene enhancers. Data presented 
here identified two such potential enhancers of the HAT1 gene. While HAT1 bound RUNX1 at 
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its promoter, although in the absence of a consensus sequence, it does not respond directly to 
RUNX1 in reporter assays. Potential enhancers were identified approximately 31 kb upstream 
and 190 kb downstream of the promoter. While interactions with these regions were 
confirmed, neither were found to behave as an enhancer in reporter assays. However, the 
data presented is consistent with the +190 kb region representing a promoter-promoter 
interaction which may be related to the formation of large interconnected transcriptional 
complexes. Such promoter-promoter interactions could at least partly explain the prevalence 
of RUNX1 binding at promoters in the absence of a consensus sequence. 
 
This study has expanded our understanding of the mechanisms by which RUNX1 affects 
transcription of its target genes and has characterised distinct modes of operation at candidate 
genes: either directly through a consensus sequence; directly in the absence of a consensus 












1.1 Transcription factors 
Transcription factors are a class of proteins which share a function in regulating and facilitating 
the expression of genes by modulating their transcription. Broadly, transcription factors fall 
into two categories: general factors, which are components of the transcription machinery 
such as RNA polymerase II; and sequence-specific transcription factors. The latter category of 
proteins contain a DNA binding domain, which interacts with specific DNA elements 
throughout the genome (Kadonaga 2004). Through interaction with sequence elements, 
transcription factors determine the expression of genes, which in turn regulate all complex 
biological processes in the cell (Prange, Singh et al. 2014). Genes coding for transcription 
factors comprise approximately 10% of all genes in the human genome (Levine and Tjian 
2003). Transcription factors are classified based on the type of DNA binding domain they 
contain. Major DNA binding domain classes include homeodomain, basic helix-loop-helix, 
leucine zipper and zinc finger transcription factors (Wingender, Chen et al. 2001). To regulate 
transcription, these factors localise to regulatory elements of DNA through amino acid motifs 
in their DNA binding domains and facilitate recruitment of the transcription machinery. 
Generally, the DNA binding domains of transcription factors recognise a specific sequence of 
nucleotides, usually a 5-6 base pair motif referred to as its consensus sequence. However, the 
sequences recognised by an individual transcription factor can be highly variable, with 
corresponding changes in binding affinity. Regulatory elements such as promoters and 
enhancers are often characterised by the presence of many consensus sequences and are 
bound by numerous transcription factors simultaneously. Regulation of a single element by 
multiple transcription factors working in a co-ordinated manner is one way in which precise 
control of transcription is achieved (Morgunova and Taipale 2017). 
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1.2 RUNX Family Transcription Factors 
The RUNX family of transcription factors, named for their binding domain’s homology to the 
drosophila Runt protein, regulate various cellular processes involved in normal development 
and cell fate determination (Kagoshima, Shigesada et al. 1993). RUNX proteins are DNA-
binding factors which form heterodimers with the ubiquitously expressed non-DNA binding 
Core Binding Factor β (CBFβ), to form the Core Binding Factor (CBF). The heterodimer has 
increased DNA binding affinity compared to the RUNX protein alone (Wang, Stacy et al. 1996). 
There are three RUNX transcription factors in mammals (Figure 1.1). RUNX1 is a master 
regulator of haematopoiesis and is vital for both the development of haematopoietic stem 
cells and the normal function of adult haematopoiesis (Okuda, Van Deursen et al. 1996). 
RUNX2 is essential for the formation of bone, and is crucial for the differentiation of 
osteocytes and chondrocytes (Komori, Yagi et al. 1997, Otto, Thornell et al. 1997, Inada, Yasui 
et al. 1999). RUNX3 is involved in neurogenesis, and when knocked out in mouse models leads 
to severe limb ataxia due to disrupted synaptic connectivity (Levanon, Bettoun et al. 2002). In 
addition to these essential functions, all three RUNX proteins have roles in other organs and 
systems (de Bruijn and Dzierzak 2017). All three are frequently disrupted in various cancers, 
demonstrating their importance in maintaining normal cellular development and function 











Figure 1.1. RUNX family members.  
Schematic representation of human RUNX protein family members. The Runt homology 
domain (orange), activation domain (purple), repression domain (red) and VWRPY motif (blue) 
are shown. Relevant amino acid positions are indicated below. Only the RUNX1B isoform is 






The Runt-related transcription factor 1 (RUNX1) gene was originally identified at the 
breakpoint of the t(8;21) fusion gene in acute myeloid leukaemia (AML) cells (Rowley 1973, 
Miyoshi, Shimizu et al. 1991). The protein was identified as a sequence-specific binding factor 
at enhancers within the Moloney murine leukaemia virus and polyomavirus genome (Speck 
and Baltimore 1987, Kamachi, Ogawa et al. 1990). RUNX1 has since been shown to be a master 
regulator of haematopoiesis.  
 
1.3.1 Structure of RUNX1 
The structure and function of RUNX1 is well described, as it has been thoroughly investigated 
as a major regulator of haematopoiesis. RUNX1 consists of a DNA binding runt homology 
domain, as well as a transactivation and repression domain, both located at the C-terminal end 
of the polypeptide and an N-terminal VWRPY motif which directs nuclear localisation (Figure 
1.1). This runt homology domain shares 92% sequence homology with the drosophila runt 
gene (Berardi, Sun et al. 1999), which is involved in sex determination, segmentation and 
neurogenesis (Kagoshima, Shigesada et al. 1993). There are three major isoforms of RUNX1 
resulting from transcription from two promoters and alternative splicing (Figure 1.2). The 
proximal promoter P2 directs transcription of the isoforms 1A and 1B, of which the first 241 
amino acids are identical but differ in alternative splicing of the carboxyl terminus. After 241 
amino acids the isoforms diverge. The 1A isoform ends after a further 9 amino acids while the 
1B isoform is much longer, containing a total of 453 amino acids. Isoform 1C is transcribed 
from the distal P1 promoter and differs from 1B only in the first 32 amino acids (Miyoshi, Ohira 
et al. 1995). Isoform 1C is expressed only during early development of definitive 
haematopoietic stem cells, while 1A and 1B are expressed throughout haematopoietic 
differentiation (Challen and Goodell 2010). Isoform 1A is more prevalent than 1B in CD34+ 
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progenitor cells in human cord blood, and its relative overexpression is linked to increased 
cellular self-renewal (Tsuzuki, Hong et al. 2007). All transcripts encode the Runt DNA binding 
domain, which forms an s-type immunoglobulin fold similar to those found in the transcription 
factors NF-κB, NFAT, p53, STAT1, and the T-domain (Berardi, Sun et al. 1999). Unlike these 
similar domains, the Runt domain is unique in that it recognises DNA through loops formed 
between β-sheets at both ends of the Ig fold. The Runt domain in RUNX1 undergoes allosteric 
change in three looping regions (L11, 9 and 5) when bound to DNA (Bäckström, Wolf-Watz et 
al. 2002), and is stabilised by heterodimerisation with CBFβ (Bartfeld, Shimon et al. 2002). The 
DNA target sequence of the Runt domain is predisposed to adopt a unique bent conformation 










Figure 1.2. RUNX1 isoforms.  
Schematic protein representation of RUNX1 isoforms A, B, and C. Amino acids which differ 




1.3.2 Function of RUNX1 
RUNX1 is required for the establishment of haematopoietic stem cells (HSCs) during 
embryogenesis and subsequent differentiation of HSCs into mature myeloid, lymphoid, and 
megakaryocyte lineages (Friedman 2009).  Two stages of haematopoiesis occur, primitive, 
involving differentiation of primitive macrophages and early erythrocytes from progenitors in 
the yolk sac for rapid development of the embryo (Palis, Robertson et al. 1999) and definitive, 
which involves generation of mature haematopoietic cells of various lineages from a common 
definitive HSC. RUNX1 is present at the earliest stages of HSC development during 
embryogenesis (Lam and Zhang 2012).  
 
Evidence for the function of RUNX1 has been obtained through knockout mouse studies, which 
disrupt the protein at the Runt homology domain and therefore prevent the function of all 
Runx1 isoforms. Runx1 heterozygous knockout mice are healthy, but double knockout mice die 
between 12.5- and 13.5-days post-conception from haemorrhaging of the central nervous 
system (Okuda, Van Deursen et al. 1996). This embryonic lethality has been further linked to 
defects in angiogenesis caused by lack of angiopoietin-1 expression (Takakura, Watanabe et al. 
2000). Analysis of Runx1 double knockout mouse embryos at 11.5-days post-conception 
identified no significant differences in the yolk sac between wild type and knockout mice, but 
the Runx1 negative embryos completely lacked haematopoiesis in the liver. Runx1-null mice 
have nucleated primary erythrocytes, consistent with yolk sac derivation. As the normal 
murine developmental cycle shifts the site of haematopoiesis from the yolk sac to the foetal 
liver at this stage, this suggests that the mice have successful primitive haematopoiesis, but 
lack definitive haematopoiesis and that RUNX1 is only necessary for the latter. More recent 
evidence indicates that RUNX1 also has a role in primary haematopoiesis, as the primitive 
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erythrocytes developing in Runx1-null mice exhibit disrupted phenotypes (Yokomizo, 
Hasegawa et al. 2008). 
 
It is clear that RUNX1 is vital for embryonic development of haematopoietic programs, and a 
role in adult haematopoiesis has also been elucidated through analysis of conditional Runx1 
knockout mice. These models demonstrate that while RUNX1 is not required for adult 
haematopoiesis in the same way as it is in the embryo, lack of Runx1 nevertheless results in 
haematopoietic abnormalities. In particular, conditional knockout of Runx1 in haematopoietic 
cells, induced using a Cre-LoxP mouse model, resulted in inefficient platelet and common 
lymphocyte progenitor production, inhibited B-and T-cell maturation, and increased 
proliferation of myeloid progenitor populations and peripheral blood neutrophils (Growney, 
Shigematsu et al. 2005). This supports evidence from Runx1 haploinsufficient mice, which have 
increased number of HSCs, but a lower number of functional long-term HSCs (Sun and 
Downing 2004). Maintenance of HSCs is impaired in Runx1 deficient cells, leading to 
exhaustion of the stem cells after the initial expansion and an eventual decline in HSC numbers 
(Jacob, Osato et al. 2010). RUNX1 impaired cells in general exhibit increased proliferative 
capacity but decreased functionality.  
 
1.4 Leukaemia 
RUNX1 is critical in establishing gene expression profiles during haematopoietic cell 
development and function, and therefore its disruption is commonly associated with the 
development of haematopoietic malignancies such as leukaemia. An estimated 4000 
leukaemia cases were diagnosed in 2018 in Australia, making it the 8th most commonly 
diagnosed cancer. Almost 2000 deaths were attributed to various leukaemias in the same year. 
While survival rates have improved steadily, 5-year survival rates remain around 60% (2010-
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2014; Australian Institute of Health and Welfare 2019). RUNX1 mutations in AML patients are 
associated with poorer prognosis, exhibiting shorter disease-free periods as well as lower 
complete remission and overall survival rates (Tang, Hou et al. 2009). The incidence of RUNX1 
mutations in AML is estimated to be between 5 and 16% and it has been proposed that AML 
with RUNX1 mutation forms a distinct clinical subtype of the disease (Jalili, Yaghmaie et al. 
2018). RUNX1 is required at several stages for maturation of haematopoietic stem cells into 
mature and specialised lineages, as well as negatively regulating renewal of immature cells.  
 
1.4.1 Disruption of RUNX1 in leukaemia 
Genetic mutations causing leukaemia have been historically thought to fall into two broad 
categories: class I mutations which lead to uncontrolled proliferation and inhibition of 
apoptosis, and class II mutations which block cellular maturation (Gilliland 2002). More recent 
studies have added complexity to this model, identifying a third class of mutations which 
facilitate epigenetic and chromatin state change, and elucidating the interdependence of 
different classes (Naoe and Kiyoi 2013). RUNX1 mutations, which generally cause loss of 
function, have been historically assigned to class II.  Loss of RUNX1 function commonly occurs 
through point mutations, deletions, or translocations (Ichikawa, Yoshimi et al. 2013), with 
disruption of RUNX1 leading to myelodysplastic syndrome, acute myeloid leukaemia, acute 
lymphoblastic leukaemia and chronic myelomonocytic leukaemia. Leukaemias with 
translocations occurring at RUNX1 or its binding partner CBFβ, including the RUNX1-ETO 
translocation, are referred to as core binding factor (CBF) leukaemia, which is more prevalent 
in younger patients and generally associated with a better prognosis. However, leukaemias 
with RUNX1 somatic mutations tend to occur in older patients and have a poorer prognosis 
(Sood, Kamikubo et al. 2017). Haploinsufficiency of RUNX1 has been linked to the inheritance 
of familial platelet disorder, a disease which predisposes its sufferers to the development of 
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AML as the second copy of the gene is vulnerable to inactivating mutations leading to full 
knockout (Song, Sullivan et al. 1999, Preudhomme, Renneville et al. 2009).  
 
Alterations which increase RUNX1 copy number can also lead to disease. RUNX1 gene 
duplications resulting from hyperdiploidy occurred in 50% of subjects in a study of Mexican 
children with ALL (Rosales-Rodríguez, Fernández-Ramírez et al. 2016). Point mutations, in 
which a single nucleotide is altered from the wild type sequence, can lead to dominant-
negative forms of RUNX1, particularly when they occur within the DNA-binding Runt domain or 
in the C-terminal region of the protein (Imai, Kurokawa et al. 2000, Michaud, Wu et al. 2002, 
Churpek, Garcia et al. 2010). One study of 470 de novo AML patients identified 63 distinct 









Figure 1.3. Locations of RUNX1 mutations. 
Figure taken from Tang, Hou et al 2009. Four kinds of mutations were identified in a study of 
470 individuals with de novo AML, missense, nonsense, frameshift, and in-frame mutations. ▴ 
and | represent the sites of mutation; X, the site of a stop codon; Ω, the site of insertion; the 
site of deletion. RD indicates repression domain; TAD, transactivation domain; UTR, 





Mutations within the Runt domain that have been identified in individuals with leukaemia 
include silent mutations; where the change in DNA has no effect on the protein sequence as 
the resulting codon is synonymous with the wild type, though the mutation may still influence 
the gene by altering splice sites or disrupting chromatin features; missense mutations, in which 
the altered base changes the coded amino acid; and nonsense or frameshift mutations which 
commonly lead to premature translational termination. An early study of individuals with AML 
and CML identified RUNX1 point mutations in six out of 117 cases (Osato, Asou et al. 1999). 
Mutations identified had various effects on RUNX1-DNA interactions as assayed by 
electrophoretic mobility shift assays (EMSA). Of these mutations, H58N occurs on the 
periphery of the Runt domain and had no discernible effect on DNA binding. At the other end 
of the Runt domain, mutation or premature termination at residue 177 prevented RUNX1-DNA 
binding, but this was restored on heterodimerisation with CBFβ due to induced conformational 
change. No DNA binding was detected for missense mutations at residues R80 and K83, but 
the mutant protein is still able to form heterodimers. Both DNA binding and 
heterodimerisation capacity was removed by a 4 base pair insertion at C72 and premature 
termination at S114 (Osato, Asou et al. 1999). Mutations also disrupted the localisation of 
RUNX1 to the nucleus. Since this study, many more mutations in RUNX1 have been identified 
in large cohorts of individuals with leukaemia (Preudhomme, Warot-Loze et al. 2000, Tang, 
Hou et al. 2009, Gaidzik, Bullinger et al. 2011, Schnittger, Dicker et al. 2011). The majority of 
RUNX1 mutations have been detected in the Runt homology domain of the protein, affecting 
its ability to bind DNA targets but not its ability to heterodimerise with CBFβ. This suggests a 
potential mechanism for the dominant-negative effects of mutant RUNX1 where sequestration 
of CBFβ, makes it unavailable for interaction with the wild type protein and in turn impairing 




In addition to mutations within the gene, RUNX1 is a common target for chromosomal 
translocations in cancer cells. The translocation resulting in the fusion of the RUNX1 gene with 
the RUNX1T1 locus, which encodes the Eight-Twenty-One (ETO) gene was the first 
translocation event to be identified in relation to cancer (Rowley 1973). Since then, 
approximately 55 different translocation partners have been identified for RUNX1, though the 
partner gene involved has only been identified in 21 of these cases (De Braekeleer, Douet-
Guilbert et al. 2011). Fusion proteins which retain the Runt domain but lose the transactivation 
domain are thought to promote leukaemogenesis by inhibiting wild type RUNX1 function. 
Most identified translocations are rare, having been only identified in a few cases, but there 
have been seven recurrent RUNX1 translocations described (De Braekeleer, Ferec et al. 2009).  
 
1.4.2 RUNX1-ETO 
One of the most commonly recurring translocations, t(8;21), in which the first five exons of the 
RUNX1 gene are fused to the Eight-Twenty-One (ETO) gene at intron 1, is present in 
approximately 12% of all AML cases (Lam and Zhang 2012). The resulting fusion protein, 
RUNX1-ETO, contains the N-terminal 177 amino acids of RUNX1, which includes the Runt 
homology domain, fused to the majority (575 amino acids) of the ETO protein. The Runt 
domain in this fusion protein is functional, allowing for both DNA binding and 
heterodimerisation with CBFβ, but replacement of the transactivation domain with the ETO 
protein disrupts usual RUNX1 transcriptional regulation (Lin, Mulloy et al. 2017). The ETO 
protein contains four evolutionarily conserved Nervy homology regions (NHR) and a nuclear 
localisation signal, which serves to direct the protein to the nucleus (Davis, McGhee et al. 
2003). The second of these NHRs is crucial for the leukaemic potential of the chimeric protein, 
as it is the site of oligomerisation to form a tetramer (Liu, Cheney et al. 2006). This homo-
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oligomeric formation and subsequent leukaemogeneis is independent of CBFβ (Kwok, Zeisig et 
al. 2009). As well as oligomerisation, the fused ETO protein acts as a transcriptional repressor 
by recruiting other factors, NCOR, SMRT, HDACs 1-3, and mSin3A, to form a corepressor 
complex (Gelmetti, Zhang et al. 1998, Wang, Hoshino et al. 1998, Amann, Nip et al. 2001). The 
formation of this complex has been demonstrated in overexpression studies, however the 
interaction between components is only weak in vivo, suggesting that the formation may be 
dynamic and context-dependent (Sun, Wang et al. 2013).  
 
1.4.3 Other RUNX1 translocations 
Other recurring translocations of the RUNX1 gene include t(16;21), t(3;21), t(1;21), and 
t(12;21) (De Braekeleer, Ferec et al. 2009). The t(16;21) translocation fuses RUNX1 to MTG16 
(Myeloid translocation gene on chromosome 16), which is an ETO family gene. The resulting 
fusion protein has properties similar to those of RUNX1-ETO in that it can repress RUNX1 
targets by recruiting corepressor complexes (Gamou, Kitamura et al. 1998). Three different 
translocation partner genes have been identified in the heterogenous t(3;21) translocation: 
EAP, EVI1 and MDS1. RUNX1-EAP translocation is out of phase, introducing a premature 
truncation and the fusion protein is proposed to act as a repressor of normal RUNX1 (Nucifora, 
Begy et al. 1993, Sacchi, Nisson et al. 1994). Fusion with EVI1 attaches two zinc-finger domains 
to the Runt domain of RUNX1, which have a negative effect on normal RUNX1 expression as 
well as encouraging proliferation and impeding apoptosis (Mitani 2004). EVI1 also exists as a 
fusion protein with MDS1, caused by alternative splicing at the MDS1-EVI1 complex locus 
(Tanaka, Oshikawa et al. 2017). The RUNX1-MDS1-EVI1 fusion protein has similar effects to the 
RUNX1-EVI1 fusion (Sood, Talwar-Trikha et al. 1999). Also similar in effect to RUNX1-EVI1, the 
t(1;21) translocation fuses the Runt homology domain to almost the entire PRDM16 protein, 
which shares significant homology to EVI1 (Stevens-Kroef, Schoenmakers et al. 2006). Most 
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commonly observed in paediatric acute lymphoblastic leukaemia, the t(12;21) is distinct from 
other translocations in that it retains the RUNX1 transactivation domain, fusing the 3’ region of 
RUNX1 and the 5’ end of ETV6. The ETV6 protein contains a repressive domain, allowing the 
fusion protein to bind to RUNX1 targets and recruit HDACs (Romana, Mauchauffe et al. 1995, 
Zelent, Greaves et al. 2004). 
 
1.5 Regulation of gene expression by RUNX1 
In vitro, the RUNX1 RHD binds to the consensus DNA sequence 5’-TG(T/C)GGT-3’ (Meyers, 
Downing et al. 1993), considered to be the canonical RUNX1 binding sequence. Electrophoretic 
mobility shift assays and X-ray crystallography studies of the RUNX1 RHD identified three 
critical arginine residues which bind to specific guanines in the DNA sequence TG(T/C)GGT 
(Tahirov, Inoue-Bungo et al. 2001). Understanding of the function of RUNX1 as a transcription 
factor has been largely driven by investigation of target genes, which have been mostly 
discovered by locating consensus sequences in gene promoters or identifying differential 
expression patterns through mRNA screens (Otto, Lübbert et al. 2003). For example, 
Interleukin 3 was identified as a potential RUNX1 target gene in T cells through the presence of 
both a canonical RUNX1 consensus sequence (TGTGGT) and a variant sequence (TGTGGG) in its 
promoter. Co-transfection, gel shift and mutagenesis experiments demonstrate the response 
of these elements to RUNX1, though the variant sequence showed a lower affinity for the 
transcription factor and its mutation did not disrupt promoter responsiveness (Uchida, Zhang 
et al. 1997). Similarly, in myeloid cells, RUNX1 has been shown to up-regulate the M-CSF 
(macrophage colony-stimulating factor) receptor (Zhang, Fujioka et al. 1994), complement 
receptor type 1 (Kim, Lee et al. 1999) and CD36 (Armesilla, Calvo et al. 1996) genes through 




On its own, RUNX1 is a relatively weak transcription factor. Heterodimerisation with CBFβ 
increases affinity for DNA binding more than 40-fold over RUNX1 alone (Gu, Goetz et al. 2000), 
but activation or repression of RUNX1 target genes often relies on cooperation with other 
transcription factors, forming large multiprotein complexes (Yoshida and Kitabayashi 2008). 
One such co-factor is yes-associated protein (YAP1), a component of the Hippo signalling 
pathway. RUNX1 binds to target promoters, such as Itch, and recruits YAP1 through 
interactions between the RUNX1 PY motif, located within the RUNX1 activation domain and 
the YAP1 WW domain (Yagi, Chen et al. 1999, Levy, Reuven et al. 2008). This interaction is 
altered in the event of DNA damage, during which YAP1 becomes phosphorylated at tyrosine 
residues and reduces its binding preference for RUNX proteins and instead binds p73 and 
activates pro-apoptotic targets (Levy, Adamovich et al. 2008). This example highlights the 
complexity of regulation of RUNX1 targets and the co-operative mechanism by which 
transcription factors affect changes in the cellular environment. Another group of commonly 
associated transcription factors are from the ETS family. One such factor, PU.1, which is 
encoded by the SPI1 gene, has been shown to act synergistically with RUNX1 to activate the M-
CSF receptor promoter (Petrovick, Hiebert et al. 1998). Co-operative binding between the two 
factors is driven by RUNX-ETS hybrid consensus sequences located at target regulatory sites 
(Zhao, Osipovich et al. 2017).  
 
RUNX1 activity is also modulated by post-translational modifications. Phosphorylation of 
RUNX1 by the ERK1/2 kinase within its transactivation domain increases its transactivation 
ability by driving association with the co-activator p300 (Tanaka, Kurokawa et al. 1996, Wang, 




1.5.1 RUNX1 regulation in the context of chromatin 
Though many investigations into the function of RUNX1 consider its target regulatory regions 
in isolation, in reality transcription factors must operate in the context of chromatin. Broadly 
speaking, chromatin exists on a dynamic spectrum between two opposing states: open and 
accessible euchromatin and densely compacted heterochromatin, in which the DNA is tightly 
wound around histone proteins. Access to the DNA by transcription factors and transcription 
machinery is restricted by heterochromatin, thus repressing gene expression. Conversion 
between the two states is vital for precise control of gene expression programs and is 
influenced by a number of factors, including DNA methylation, histone modifications or 
variants, and recruitment of chromatin remodelling proteins such as the SWI/SNF complex 
(Kassabov, Zhang et al. 2003, Choy, Wei et al. 2010, Gardner, Allis et al. 2011).  
 
RUNX1 is capable of influencing the formation of a transcriptionally active euchromatin state 
through interaction with chromatin modifying co-factors such as p300/CBP, KAT6A, PML, 
PRMT1, and HIPK2 (Yoshida and Kitabayashi 2008, Brettingham-Moore, Taberlay et al. 2015). 
Additionally, while RUNX1 was initially characterised as a transcriptional enhancer, it has since 
become clear that it also serves a repressive function in some circumstances (Durst and 
Hiebert 2004). This is demonstrated at the CD4 promoter in mice (Taniuchi, Osato et al. 2002, 
Wheeler, VanderZwan et al. 2002) and the p21 promoter in human cell lines (Lutterbach, 
Westendorf et al. 2000). Repression occurs through recruitment of corepressors mSin3 or 
TLE/Groucho through the repressive domain of the RUNX1 protein and also through repressive 
chromatin modifications caused by recruitment of the histone methyltransferases SUV39H1, 
PRMT4, and PRMT6, and subsequent histone deacetylase binding (Aronson, Fisher et al. 1997, 
Lutterbach, Westendorf et al. 2000, Reed-Inderbitzin, Moreno-Miralles et al. 2006, 
Brettingham-Moore, Taberlay et al. 2015). The effect of RUNX1 on transcription is therefore 
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dependent on the context in which it interacts with DNA and the composition of the 
transcriptional complex in which it is acting, having influences on both transcriptional activity 










Figure 1.4. RUNX1 recruits both activating and repressive cofactors. 
RUNX1 can act as a transcriptional activator or repressor dependent on the balance of 
coactivators/corepressors associated with it at a particular time. RUNX1 can recruit 
coactivators or corepressors as well as epigenetic modifiers to affect transcriptional activation 





1.6 A genome-wide view of transcription factor localisation 
The behaviour of transcription factors has been extensively studied using various in vitro 
technologies, such as protein binding microarrays, high-throughput systematic evolution of 
ligands by exponential enrichment (HT-SELEX), and DNA immunoprecipitation paired with 
either microarray or sequencing analysis (Levo and Segal 2014). These techniques provide 
precise quantitative data on affinities of a wide range of transcription factors for DNA and have 
proven invaluable in identifying transcription factor binding sites. Additionally, a range of 
technologies have been employed to examine transcription factor function and binding 
context in vivo, including chromatin immunoprecipitation paired with microarrays or 
sequencing (ChIP-chip or ChIP-seq), assay for transposase-accessible chromatin using 
sequencing (ATAC-seq), and assays for occupied regions of genomes from affinity-purified 
naturally isolated chromatin (ORGANIC) (Levo and Segal 2014). While there is often 
considerable agreement between transcription factor occupancy predicted based on in vitro 
binding affinities and that observed through in vivo assays, these assays have also frequently 
revealed unexpected localisation of transcription factors. The difference between transcription 
factor behaviour in vitro and in vivo highlights the complexity of transcription factor function 
and represents a gap in current understanding of transcription factor regulatory mechanisms. 
 
Genome-wide technologies such as ChIP-seq allow us to obtain a more wholistic view of 
transcription factor localisation than was possible through analysis of individual genes in 
isolation. Chromatin immunoprecipitation techniques involve cross-linking proteins such as 
transcription factors to DNA using formaldehyde followed by isolation and sonication of 
genomic DNA to generate protein-bound fragments. These fragments are precipitated with 
protein-specific antibodies and the cross-links are reversed. Originally, ChIP analyses identified 
genomic regions by PCR with primers for regions of interest, comparing experimental products 
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to those generated from precipitation with unrelated antibody or IgG. While these studies are 
useful in confirming enrichment of protein binding to specific candidate regions, they are 
limited in their scope for identifying novel binding sites. To overcome this limitation, more 
recent techniques pair ChIP assays with detection technology such as micro-arrays (ChIP-chip) 
or various Sanger sequencing processes (ChIP-SAGE, ChIP-STAGE and ChIP-GMAT), reviewed in 
Hoffman & Jones, 2009 (Hoffman and Jones 2009). Pairing chromatin immunoprecipitation 
with flow cell sequencing (ChIP-Seq) delivers improved coverage, provides more detailed 
information, and is the highest resolution ChIP technique currently in use, allowing analysis of 
genome-wide protein binding in an unbiased manner. 
 
1.6.1 A more complex model of transcription factor binding 
A genome wide perspective has provided new insights into the mechanism of gene regulation 
by another transcription factor, Myc. Myc comprises one half of the Myc-Max heterodimer, 
which has been shown to bind to E-box sequence elements (CACGTG) in vitro (Blackwell, 
Kretzner et al. 1990). However, a study by Guo and colleagues interrogating the binding of Myc 
using ChIP-seq data identified that a large proportion of binding occurs in the absence of the 
canonical E-box sequence (Guo, Li et al. 2014). In fact, the occupancy of Myc on a genome-
wide scale correlates far better with loci bound by RNA Polymerase II (Pol II) than sites of E-box 
elements, being found on average 100 bp upstream of promoter proximal paused Pol II. The 
relaxed sequence specificity of the Myc-Max heterodimer was demonstrated using 
electrophoretic mobility shift assays (EMSA) on 26 bp fragments of DNA containing either the 
E-box, related, or unrelated sequence at the centre, and through protein binding microarrays 
with all possible 8 bp sequences. Even sequences with high binding affinity, which may 
represent possible novel consensus sequences, were less well correlated with Myc occupancy 
than Pol II. The study concluded that expected sequence specificity is insufficient to account 
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for the presence of Myc across the genome. The authors propose a mechanism by which Myc 
is recruited by “Mediator”, another factor which associates with Pol II, and then binds to DNA 
in a non-sequence-specific manner at promoters. 
 
In addition to Myc, there is evidence that other transcription factors also have mechanisms of 
transcriptional regulation that do not require their accepted consensus sequences.  NF-κB has 
been shown to bind active enhancers, more than half of which do not contain its canonical 
consensus sequence (Kolovos, Georgomanolis et al. 2016). Direct binding of FOXM1 to DNA 
through its DNA binding domain to sequences not containing the canonical forkhead 
consensus sequence has been demonstrated by ChIP (Sanders, Gormally et al. 2015). Finally, 
low-affinity variant consensus sequences for the GLI transcription factor have been shown to 
be responsive to moderate concentrations of GLI, demonstrating the functionality of non-
consensus sequence-containing promoters (Winklmayr, Schmid et al. 2010). 
 
In light of the analysis described above, it is apparent that there is a gap in understanding of 
RUNX1 binding and function. While algorithms designed to locate consensus sequences and 
transcription studies to examine differential expression profiles are valuable methods for 
identifying consensus sequence mediated RUNX1 gene targets, they have not captured the 
whole range of RUNX1 action. This is because reliance on promoter consensus sequence 
identification overlooks targets which differ substantially from the canonical TG(T/C)GGT 
sequence, and misses uncharacterised distal regulatory elements such as enhancers. 
Additionally, expression analysis relies on dramatic changes in expression levels which may not 




Recent genome-wide studies of RUNX1 indicate that the recruitment of RUNX1 to its 
consensus sequence in gene promoters represents only a small proportion of global RUNX1 
binding throughout the genome (Ptasinska, Assi et al. 2014, Trombly, Whitfield et al. 2015). 
These studies investigated the co-localisation of the leukaemia associated fusion protein 
RUNX1-ETO with a variety of other transcription factors, such as RUNX1 itself, p300 and N-CoR 
on a genome-wide scale, and in doing so uncovered new information about the occupancy of 
RUNX1. In a manner reminiscent of Myc, genome-wide studies revealed that the majority of 
RUNX1 binding occurs outside of gene promoters, largely within genes and in intergenic 
regions. Further, many binding sites were entirely devoid of RUNX consensus sequences. 
Findings from these genome-wide studies require a reassessment of the accepted mechanism 
of RUNX1 transcriptional action. 
 
1.7 Research aims 
RUNX1 is an important transcription factor which governs many of the processes involved in 
haematopoiesis. Disruption of RUNX1 regulatory networks frequently contributes to the 
development of leukaemia. It is therefore vital to understand the mechanism by which RUNX1 
operates to maintain these networks. ChIP-seq databases which detail RUNX1 binding on a 
genome-wide scale provide a valuable resource for identifying novel regulatory mechanisms 
not detected in single target gene studies. Analysis of ChIP-seq data has identified RUNX1 
binding sites which are not associated with canonical consensus sequences. Hence, the 
hypothesis of this study is as follows: 
 
The function of RUNX1 is determined by the manner in which it is recruited to target genes, 
which occurs either directly through its consensus sequence or indirectly through interaction 




Aims:  Overall objective: To characterise the different modes of action of RUNX1 in myeloid 
cells 
• Aim 1: To analyse the genomic and sequence context of RUNX1 localisation through 
analysis of ChIP binding sites in publicly available data 
• Aim 2: To characterise the different modes of action of RUNX1 at gene promoters 







2 Materials and Methods 
 
2.1 Cell Culture 
Commercially available leukaemic cell lines were used to determine expression of candidate 
genes, response to RUNX1 overexpression and chromatin interactions involving candidate 
promoters. K562 cells are derived from a CML patient in terminal blast crisis. They are 
granulocytic and highly undifferentiated. KG1a cells are derived from KG-1 cells, which are 
from the bone marrow of an AML patient, and are less mature than the parent lineage. 
Kasumi-1 cells are myeloblasts with the t(8;21) translocation, resulting in the production of the 
RUNX1-ETO fusion protein. 
 
2.1.1 Culture conditions 
K562, KG1a and Kasumi-1 cells were obtained from American Type Culture Collection and were 
cultured in Gibco® Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies, 
USA), containing D-glucose (2 g/L), glutathione (1 mg/L), hydroxyethyl 
piperazineethanesulfonic acid (HEPES; 6 g/L), and sodium bicarbonate (2 g/L, added on 
preparation). Media was supplemented with heat-inactivated foetal bovine serum (FBS; 10% 
for K562 and KG1a cells, 20% for Kasumi-1 cells; Life Technologies, USA) and penicillin (100 
U/mL)/streptomycin (100 µg/mL; Sigma-Aldrich, USA). K562 and KG1a cells were subcultured 
every 2-3 days to maintain a concentration between 1 x 105 and 1 x 106 cells/mL. Kasumi-1 
cells were subcultured weekly to maintain a similar cellular concentration. All cell lines were 




2.2 Cloning of candidate gene promoters 
Promoters of candidate genes were cloned into the pXPG plasmid (Bert, Burrows et al. 2000), 
which contains a luciferase gene, for use in reporter assays to determine the effects of RUNX1 
overexpression on these regions. 
 
2.2.1 Primer design 
The promoter regions of candidate genes were cloned into the pXPG plasmid. Primers (Tables 
2.1 and 2.2) were designed and checked for specificity for each promoter using the Primer-
BLAST program (Ye, Coulouris et al. 2012) to amplify a region of approximately 500-1000 bp in 
size incorporating both the TSS and the site of a RUNX1 ChIP peak (Trombly, Whitfield et al. 
2015). Additional primers (also described in Table 2.1) were designed to amplify a region 
containing only the proximal ChIP peak in the KAT7 promoter. Recognition sites for XhoI and 
HindIII restriction enzymes were included at the 5’ end of forward and reverse primers 
respectively, as well as five random nucleotides for increased restriction enzyme digestion 




Table 2.1. Primers for amplification of HAT promoters. 
The primers used to amplify promoter regions of consensus sequence absent candidates are 
detailed. Restriction enzyme recognition sites are underlined, and the expected size of the PCR 
fragment is listed. 
Promoter Primer Sequences Fragment Size 
HAT1 Forward: 5’-TGCTACTCGAGTTCTCCCGCAACTGAAACTC-3’ 500 bp 
Reverse: 5’-TGCTAAAGCTTATTTCCGAGCTACGATCACC-3’ 
KAT6A Forward: 5’-TGCTACTCGAGGGGTTAAGACGGGTGCTTCT-3’ 765 bp 
Reverse: 5’-TGCTAAAGCTTGGAAGGACAGCCGAGATCC-3’ 
KAT6B Forward: 5’-TGCTACTCGAGAAGGAGCTGGCGACTGAG-3’ 504 bp 
Reverse: 5’-TGCTAAAGCTTGGTCATCTCGCTTCCACATAA-3’ 




Forward: 5’-TGCTACTCGAGCCCGCGACATCAACTAACTC-3’ 568 bp 
Reverse: 5’-TGCTAAAGCTTTTTTCCTTCACTTCCGGCTG-3’ 
KAT2A Forward: 5’-TGCTACTCGAGCACCACACTACTGCAGAACTG-3’ 596 bp 
Reverse: 5’-TGCTAAAGCTTGGGGTGGGAGTCGGAATC-3’ 






Table 2.2. Primers for amplification of ARHGAP promoters. 
The primers used to amplify promoter regions of consensus sequence present candidates are 
detailed. Restriction enzyme recognition sites are underlined, and the expected size of the PCR 
fragment is listed. 
Promoter Primer Sequences Fragment Size 
ARHGAP1 Forward: 5’-TGCTACTCGAGTGAGGAGAAAGCTGACCACA-3’ 814 bp 
Reverse: 5’-TGCTAAAGCTTCTCCCGCTCTCTTCTATCCC-3’ 
ARHGAP4 Forward: 5’-TGCTACTCGAGCCTCCCACCAAATTGAAGCC-3’ 964 bp 
Reverse: 5’-TGCTAAAGCTTGTCGAACCCCACTGCTCC-3’ 
ARHGAP9 Forward: 5’-TGCTACTCGAGACAGTAGGTACCAAAGGCCC-3’ 487 bp 
Reverse: 5’-TGCTAAAGCTTCTCACTTCCTGTTGCCAACTT-3’ 







2.2.2 PCR amplification of candidate promoters 
Genomic DNA (gDNA) was isolated fromK562 cells using the AllPrep DNA/RNA Mini Kit 
(Qiagen, USA) and used as template DNA for the PCR amplification of all candidate promoters. 
A 25 µL reaction containing 1X Phusion® High-Fidelity PCR Master Mix with GC Buffer (Thermo 
Fisher Scientific, USA) and 0.5 µM primers (Tables 2.1 and 2.2) was used to amplify the gDNA 
as per manufacturer’s instructions. The PCR reaction was carried out using a Verti® 96 Well 
Thermal Cycler (Applied Biosystems™, USA) under the following cycling conditions: initial 
denaturation at 98°C for 30 seconds, followed by 35 cycles consisting of 30 seconds at 98°C, 30 
seconds at 68-72°C (depending on primer set) and 30 seconds at 72°C. After the final cycle, a 
further 72°C extension step for 7 minutes was included. PCR products were visualised by 
electrophoresis on 2% agarose gels and amplified promoter regions were excised from the 
gels. Products were extracted from excised gel bands using the Illustra GFX DNA and Gel Band 
Purification kit (GE Healthcare, USA) as per manufacturer’s instructions. Promoter DNA was 
eluted in 20 µL Elution Buffer Type 4.  
 
2.2.3 Ligation of PCR products into pXPG 
Purified PCR products and pXPG plasmid were digested with XhoI and HindIII restriction 
enzymes (New England Biolabs, USA) for 3 hours at 37°C. Digested DNA was purified from the 
reaction mixture using the Illustra GFX DNA and Gel Band Purification kit (GE Healthcare, USA) 
as per manufacturer’s instructions and eluted in 20 µL Elution Buffer Type 4. Purified digested 
fragments and plasmid were quantified using a NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies, USA). Promoter fragments (insert) and pXPG plasmid (vector) were 
ligated in a 10 µL reaction containing 1 µL T4 DNA Ligase, 1X T4 DNA Ligase Reaction Buffer 
(New England Biolabs, USA), 20-50 ng digested plasmid DNA and sufficient volume of digested 
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promoter fragment DNA to ensure a 1:3 vector to insert ratio. Reactions were incubated at 
room temperature overnight. 
 
2.2.4 Plasmid transformation and isolation 
Ligated plasmid vector DNA (5 µL) was transformed into StrataClone SoloPack Competent Cells 
(25 µL; Agilent, USA) as per manufacturer’s instructions. Transformed cells (100 µL) were 
plated on agar plates containing 100 µg/mL ampicillin (Sigma-Aldrich, USA) and incubated 
overnight at 37°C. Colonies were screened for successfully ligated vector by PCR using GoTaq 
Green Master Mix (Promega, USA) as per manufacturer’s instructions, with cycling conditions 
as described in Section 2.2.2. Plasmid DNA was isolated from 1 mL overnight cultures of 
positive PCR colonies using the QIAprep Spin Miniprep kit (Qiagen, USA) as per manufacturer’s 
instructions and eluted in 20 µL Buffer EB. Plasmid DNA (2 µL) was analysed by restriction 
enzyme digest and gel electrophoresis to confirm recombinants. Glycerol stocks were 
prepared by addition of 850 µL glycerol (Sigma-Aldrich, USA) to 150 µL bacterial culture and 
stored at -80°C. 
 
2.2.5 DNA sequencing 
Recombinant plasmids, as confirmed by PCR and restriction enzyme digest, were sequenced 
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) to verify 
the identity of the insert and ensure that no mutations had occurred in the promoter. A 10 µL 
reaction containing 0.25 µL BigDye® Terminator, 1.75 µL BigDye® Terminator sequencing 
buffer, 0.528 µM of either the forward or reverse PCR primer used to amplify the initial 
fragment (Tables 2.1 and 2.2), and approximately 200 ng of purified plasmid DNA. 
Alternatively, inserts were amplified from plasmid DNA using Phusion® High-Fidelity PCR 
Master Mix with GC Buffer (Thermo Fisher Scientific, USA) as described in Section 2.2.2, 
32 
 
purified by agarose gel electrophoresis and extracted from gel bands using the Illustra GFX 
DNA and Gel Band Purification kit (GE Healthcare, USA). The sequencing reaction was prepared 
as above, using 20 ng PCR amplified insert. The reaction was conducted using a Verti® 96 Well 
Thermal Cycler (Applied Biosystems™, USA) under the following cycling conditions: initial 
denaturation at 96°C for 1 minute, followed by 25 cycles consisting of 10 seconds at 96°C, 5 
seconds at 50°C and 4 minutes at 60°C. Sequencing products were purified using the 
Agencourt® CleanSEQ® kit (Agencourt Bioscience Corporation, USA) and eluted in 40 µL water. 
Sequencing was conducted using an ABI Prism® 310 Genetic Analyser (Applied Biosystems, 
USA) and data was collected using 310 Data Collection and Sequence Analysis Software 
(Applied Biosystems, USA). Sequencing files were aligned to the reference promoter sequence 
and analysed for mutations using the Sequencher 4.10.1 program (Gene Codes Corporation, 
USA). 
 
2.2.6 Generation of enhancer plasmid constructs 
Potential enhancer regions were cloned into promoter plasmids upstream of the promoter 
insert in both the forward and reverse orientation. Primers were designed to encompass 
regions of interest at 31 kb upstream and 190 kb downstream of the HAT1 promoter, 100 kb 
upstream of the KAT6A promoter, as well as the distal RUNX1 ChIP peak of the KAT7 promoter 
as described in Section 2.2.1 (Table 2.3). Specifically, primers were designed to include either a 
XhoI restriction site on each primer (HAT1+190 kb and KAT7 distal) or as two pairs of forward 
and reverse primers, with a XhoI site on either the forward or reverse primer and a BamHI site 
on its pair (HAT1-31 kb and KAT6A-100 kb). Fragments and promoter plasmids (HAT1-pXPG for 
HAT1 enhancer fragments and KAT7 distal site) were digested with the appropriate restriction 
enzymes and ligated, either non-specifically (HAT1+190 kb and KAT7 distal) or in forward and 
reverse direction (HAT1-31 kb and KAT6A-100 kb) as described in Section 2.2.3. Successfully 
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ligated plasmids were identified, and the inserts were confirmed for both identity and insert 




Table 2.3. Primers for amplification of enhancer regions. 
The primers used to amplify candidate enhancer regions are detailed. Restriction enzyme 
recognition sites are underlined, and the expected size of the PCR fragment is listed. 
Enhancer Primer Sequences Fragment Size 
KAT7 distal site 5’-TGCTACTCGAGGCCTCGTAACTCTCTGCTCA-3’ 234 bp 
5’-TGCTACTCGAGGAGTTAGTTGATGTCGCGGG-3’ 
HAT1+190k 5’-TGCTACTCGAGCCTTGCCCAGCGCGA-3’ 534 bp 
5’-TGCTACTCGAGTCTGGGCACCGATGTACTTT-3’ 
HAT1-31k Fwd 5’-TGCTAGGATCCTGACGATATGCAAAACAGTAAATGA-3’ 524 bp 
5’-TGCTACTCGAGCATGTGGGACTCAGTGGGAC-3’ 
HAT1-31k Rev 5’-TGCTAGGATCCCATGTGGGACTCAGTGGGAC-3’ 524 bp 
5’-TGCTACTCGAGTGACGATATGCAAAACAGTAAATGA-3’ 
KAT6A-100k Fwd 5’-TGCTAGGATCCTAAGTGTTGGAGCGGGTCA-3’ 744 bp 
5’-TGCTACTCGAGGGGCGCTGGAGTATGTG-3’ 







2.3 Luciferase reporter assays 
Luciferase reporter assays were conducted to determine the response of constructed reporter 
plasmids to RUNX1 (pCMV5-AML1B; Addgene, USA; Meyers and Hiebert, 1995) RUNX1-ETO 
(pCMV5-AML1-ETO; Addgene, USA, Meyers and Hiebert, 1995), FLI-1 (Addgene, USA), and 
combinations thereof compared to CMV control (RcCMV; Invitrogen, USA) in K562 cells. 
 
2.3.1 Plasmid preparation 
Starter cultures of reporter plasmids were prepared by inoculating 1 mL lysogeny broth (L-
broth) supplemented with 100 µg/mL ampicillin (Sigma-Aldrich, USA) from glycerol cultures. 
Cultures were incubated at 37°C with shaking for 6 hours, then added to 99 mL L-broth (with 
ampicillin) and incubated for a further 16 hours overnight. The plasmid DNA was extracted and 
purified using the Qiagen Plasmid Plus Maxi Kit (Qiagen, USA) as per manufacturer’s 
instructions and eluted in 100 µL Buffer EB. Purified plasmid DNA was quantified using a 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, USA) and diluted to 1000 
ng/µL with water.  
 
2.3.2 Transfection of myeloid cell lines 
K562 cells were subcultured 24 hours before transfection to produce a growing culture at 
approximately 5 x 105 cells/mL. Cells (4.5 x 106 cells in 300 µL RPMI with 20% FBS) were 
transfected in duplicate, with 10-15 µg plasmid (reporter with or without transcription factor 
plasmid) added to each, by electroporation in a Gene Pulser® electroporation cuvette at 270 V, 
950 µF, and infinite resistance with a Bio-Rad Gene Pulser® XCell™ (Bio-Rad, USA). For some 
transfections, plasmids were supplemented with RcCMV plasmid to ensure an equal amount of 
plasmid in each transfection. Transfected cells were supplemented with 1 mL RPMI (10% FBS) 
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and allowed to recover for 10 minutes. Duplicate transfections were combined and made up to 
10 mL with RPMI (10% FBS). Cells were incubated at 37°C and 5% CO2 for 24 hours post-
transfection. Cells were then harvested by centrifugation at 500 g for 5 minutes, washed with 
1 x phosphate buffered saline (PBS; Thermo Fisher Scientific, USA) and recentrifuged. Cell 
pellets were resuspended in 100 µL 1 x Lysis buffer (Promega, USA) and stored at -20 °C. 
Protein was isolated from cell lysates by centrifugation at 13,000 g for 5 minutes and retention 
of the supernatant, which was stored at -20°C.  
 
2.3.3 Quantitation of protein by Bradford assay 
Protein concentration of cell lysates was determined by Bradford assay. Aliquots of bovine 
serum albumin (BSA, New England Biolabs, USA) at concentrations of 0.1, 0.2, 0.3, 0.4 and 0.5 
mg/mL were prepared for a standard curve. Cell lysates were diluted 1 in 25. Protein Assay Dye 
Reagent Concentrate (BioRad, USA) was diluted 1 in 5 and 990 µL added to 10 µL diluted lysate 
or standard. Protein absorbance was measured at 595 nm after 5 minutes using a SpectaMax® 
Plus384 Microplate Reader Spectrophotometer (Molecular Devices, USA). A standard curve was 
constructed from BSA standard absorbances using Microsoft® Excel and protein concentration 
of lysates was determined.  
 
2.3.4 Quantification of reporter construct activity by luciferase assay 
The activity of reporter constructs post-transfection was analysed using the Luciferase 
Reporter System (Promega, USA). An aliquot of 10 µg of protein was added to alternating wells 
of a 96 well plate (Greiner Bio-one, Germany), leaving adjacent wells vacant, and made up to 
100 µL with 1X Lysis Buffer (Promega, USA). Luciferase reagent (100 µL) was added to each 
well and the luminescence was measured using a 2.5 second integration time on a Veritas™ 




2.4 Analysis of mRNA expression by reverse transcription quantitative PCR 
Gene expression was analysed in leukaemic cell lines by reverse transcription quantitative PCR 
(RT-qPCR) from extracted mRNA. 
 
2.4.1 RNA extraction 
RNA was extracted from cells using TRI Reagent® (Sigma-Aldrich, USA) as per manufacturer’s 
instructions. Briefly, cell pellets (approximately 4 x 106 cells) were lysed by addition of TRI 
Reagent® (500 µL) and incubated at room temperature for 5 minutes. RNA was isolated from 
lysed samples by solvent extraction. Chloroform (100 µL) was added and samples were shaken 
vigorously for 15 seconds before resting at room temperature for 10 minutes. Samples were 
centrifuged at 13,000 g for 15 minutes at 4°C and the top aqueous phase containing RNA was 
retained. RNA was precipitated overnight at -20°C by addition of isopropanol (250 µL). 
Precipitated RNA was collected by centrifugation, washed with 70% ethanol and resuspended 
in diethylpyrocarbonate treated water. RNA was quantified using a NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies, USA). 
 
2.4.2 cDNA synthesis 
cDNA was synthesised from RNA samples using the iScript™ cDNA synthesis kit (Bio-Rad, USA) 
as per manufacturer’s instructions. Briefly, a 20 µL reaction consisting of 1 x iScript Reaction 
Mix, iScript Reverse Transcriptase (1 µL) and RNA (up to 1 µg) was prepared. The reaction was 




2.4.3 Reverse transcription quantitative PCR 
RT-qPCR primers (Table 2.5) were designed for each candidate gene to amplify between 50 
and 150 bp of mRNA, ensuring that the transcript crosses an exon boundary by locating each 
primer in adjacent exons, using the Primer-BLAST program (Ye, Coulouris et al. 2012). 
Synthesised cDNA (100 ng) was amplified using the SensiFAST™ SYBR® No-ROX kit (Bioline, UK) 
in a 25 µL reaction containing 1 x SensiFAST™ Master Mix, DMSO (0.75 µL) and forward and 
reverse primers (1.25 nmol). Reactions were conducted using a Corbett Rotorgene 6000 
(Qiagen, USA) with the following conditions: initial denaturation at 95°C for 3 minutes followed 
by 40 cycles consisting of 95°C for 10 seconds, 60°C for 10 seconds, and 72°C for 20 seconds, 
with a final extension at 72°C for 3 minutes. The amplification of human Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or β2-Microglobulin mRNA transcripts was conducted in 
parallel with candidate genes to normalise for differences in synthesis or input. To confirm that 
the qPCR reaction amplified a single product, melt curves were conducted for each primer pair 
over the range 60-95°C and analysed for the presence of a single peak. Products were 
visualised by gel electrophoresis and serially diluted to generate standard curves for 




Table 2.4. Primers for RT-qPCR analysis. 
Primers designed to detect levels of transcripts for candidate and control genes and the 
expected size of the fragment are detailed. 
Gene Primer Sequences Fragment Size 
HAT1 5’-CGGGAAAAATTAATGCAAGG-3’ 138 
5’-TTGTTCGGCATCACTCATGT-3’ 
KAT6A 5’-ACTCCACCACCTACGAATGC-3’ 91 
5’-AAGCTTTGCCATGTGATCCT-3’ 
KAT6B 5’-TTGCTTCAAGAATGCTGACC-3’ 85 
5’-TTCGGGATTGTCTTTACTGC-3’ 
KAT7 5’-GGGAAAACACCTAGTTTTAAAGAGA-3’ 53 
5’-TGGCTATCCACTCATCAATCA-3’ 
KAT2A 5’-GCCCCTGACTACTACGAGGTC-3’ 59 
5’-CGCTCAGTCATGGTCTTCAG-3’ 
KAT2B 5’-TAAGGTTCCCCATGGATCTG-3’ 50 
5’-CCTATTCTTGAGGCGTTCACTC-3’ 
ARHGAP1 5’-TTGTGTTTAGTGCCTGTCGAA-3’ 89 
5’-GTACTGGTCCAGGGTGTGCT-3’ 
ARHGAP4 5’-ACACGTGGAGGTGGATAAGG-3’ 52 
5’-CTTAAACACAGAGTCCATGTTCTG-3’ 
ARHGAP9 5’-AACAGCCAGGACAAGAAGGT-3’ 72 
5’-CTCCGGTGACCACATGAATG-3’ 
ARHGAP12 5’-CATTCGCTTCATCAACCTCA-3’ 101 
5’-CTCTCTCGAAGGCATCACG-3’ 
ARHGAP6 5’-GCAACAGGACTGTGACCTGA-3’ 51 
5’-TGTCCATCTTTGGGAATGGT-3’ 










2.5 Chromatin conformation capture 
Spatial proximity of the HAT1 promoter region to potential enhancers was analysed in KG1a 
cells using chromatin conformation capture (3C). 
 
2.5.1 3C primer design 
Digestion sites for the selected restriction enzyme (MboI) were mapped across the region from 
the ChIP peak in the HAT1 promoter to potential enhancers at 31 kb upstream and 190 kb 
downstream of the TSS. Regions of DNA between restriction sites were selected for analysis to 
give an even spread across the region (Figure 5.8). One primer was designed in the promoter 
region within 50 bp of the MboI restriction site, and two primers were designed for each 
selected region using the Primer-BLAST program (Ye, Coulouris et al. 2012) to generate 




Table 2.5. Primers for 3C analysis of HAT1+190k region. 
Primers designed for each end of selected fragments generated by restriction enzyme digest 
for 3C. The location of the fragment relative to the HAT1 promoter ChIP peak and the expected 
size of the product are detailed.  
Fragment location Primer Sequence Product Size 
Promoter 5’-CGGGTTGATTCGTCCTTCCT-3’ 
 
7,957-8,597 bp 5’-CAAGCAATTGGAAGAGAAAATGTTT-3’ 132 
5’-TTGTCCATTGGTATCTTCAGGGATT-3’ 69 
11,801-12,368 bp 5’-TACTCCTGTATTATTTCCCCCTTC-3’ 66 
5’-AGATGAAAGTGTGCCACAAAGAA-3’ 153 
21,729-22,505 bp 5’-TGGACGGAAAGGGACTGCT-3’ 116 
5’-GGCACATAATGTTGTTCTGTCC-3’ 106 
45,168-45,592 bp 5’-CATAAATATTCCTTGGGCCACTTT-3’ 70 
5’-TGGCAACCACATAAATAGGCTAGT-3’ 139 
79,157-79,764 bp 5’-GCCACTTCCTGCATATAAGTATGA-3’ 124 
5’-GTCCAGCAAATAGTGCCGGG-3’ 106 
105,763-106,162 bp 5’-CCTACTGACTCAAATCCATATGTTC-3’ 134 
5’-GTTGGCCAGGATGGTCTTGA-3’ 69 
155,933-156,333 bp 5’-TCAGTCTTCAGTGATTCAGAAGC-3’ 65 
5’-TTTGGTTCTCTAAACCTGTTGTGGT-3’ 67 
173,760-174,499 bp 5’-CCAACGCACTACCCTCCA-3’ 91 
5’-ATCCGTCCGCTGTCCTCATT-3’ 120 
188,436-189,983 bp 







Table 2.6. Primers for 3C analysis of HAT1-31k region. 
Primers designed for each end of selected fragments generated by restriction enzyme digest 
for 3C. The location of the fragment relative to the HAT1 promoter ChIP peak and the expected 
size of the product are detailed.  
Fragment location Primer Sequence Product Size 
Promoter 5’-CTCTCTGGCCCTAGGAAAGTTTC-3’ 
 
4,354-5,005 bp 5’-TTCAACATGAGCCGGTCCATTT-3’ 139 
5’-GGGGGAATTTAGAGATGGGGATTA-3’ 131 
7,683-8,181 bp 5’-GACCTTCACGGGTGCACAAG-3’ 62 
5’-GGCGGAAGGTGAGTAAGCAA-3’ 78 
12,087-12,420 bp 5’-TGGAGCAAGGTAAGAATCTCCTG-3’ 83 
5’-GATTGCAGATAACGGGAAAAGTCA-3’ 109 
13,632-13,987 bp 5’-TTGGTATAATGCGGAGGCCCC-3’ 122 
5’-CCACACATAGTCCCACACCTATC-3’ 140 
17,818-18,291 bp 5’-TAACACTTATCTCAGTGCCTGCT-3’ 98 
5’-TCATCTACTGGGCAGTTGCTTC-3’ 68 
18,920-19,146 bp 5’-GAATTGGGATATGCCCAGGAA-3’ 106 
5’-GCAATCCAAGGACACAATGACC-3’ 71 
26,381-26,892 bp 5’-CTTCCTCACAGCCTGACTCTAA-3’ 94 
5’-TGAAAACATACACAGGGTCGGG-3’ 114 
30,278-31,093 bp (Region 
of Interest 1) 
5’-AGACTTTTGGAATGGGAAGGAAC-3’ 51 
5’-CTGTCCCTAGCTCTTTGACAACTTT-3’ 122 
31,268-31,626 bp (Region 







2.5.2 Fixation of cells with formaldehyde 
KG1a cells were cultured to a concentration of 5 x 105 cells/mL and aliquots of 5 million cells in 
25 mL RPMI medium were prepared. Cells were incubated with 1% formaldehyde at room 
temperature for 10 minutes. The reaction was quenched by addition of 2.1 mL of 1M glycine 
and incubation on ice for 5 minutes. To extract fixed nuclei, cells were washed and 
resuspended in 1 mL nuclei buffer (consisting of 10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 
0.1 mM EDTA, pH 8, 0.5% Igepal, 56 ng/mL spermine and 28 ng/mL spermidine) with 1 µL/mL 
Complete EDTA-Free Protease Inhibitor Cocktail (Roche Applied Science, Switzerland) and 
incubated on ice for 15 minutes with occasional agitation.  
 
2.5.3 Restriction enzyme digestion of chromatin 
Nuclei were washed and resuspended in CutSmart Buffer (358 µL; New England Biolabs, USA). 
SDS (10%, 11 µL) was added and the solution was incubated at 37°C for 1 hour with constant 
agitation. The reaction was returned to ice and TritonX-100 (10%, 75µL) was added and 
carefully mixed. MboI (500 U) was added and the reaction was incubated at 37°C overnight.  
 
2.5.4 Ligation and purification of digested chromatin 
Digested chromatin was placed on ice and ligated in-nucleus by addition of 10 x Ligation Buffer 
(820 µL; New England Biolabs, USA) and BSA (82 µL, 10 mg/mL) in 6.71 mL Nuclease-free 
water. Blunt/TA ligase master mix (250 µL; New England Biolabs) was added and the mixture 
was incubated at room temperature for 4 hours. Ligated chromatin was treated with 
Proteinase K (50 µL, 10 mg/mL, incubated overnight at 65°C followed by another addition of 50 
µL and 2 hours further incubation) and RNase A (12.5 µL, incubated at 37°C for 30 minutes) 
and purified by phenol:chloroform extraction. Extracted DNA was ethanol precipitated 
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overnight at -20°C, collected by centrifugation, washed with 70% ethanol and resuspended in 1 
x TE Buffer. Samples were stored at -20°C. 
 
2.5.5 Analysis of 3C products by qPCR 
Ligated chromatin was analysed by qPCR for the presence of chromatin regions ligated to 
candidate promoters. SYBR Premix Ex Taq II (Tli RNase H Plus) (Takara Bio Inc., USA) was used 
for analysis as per manufacturer’s instructions. Briefly, a 25 µL reaction containing 1 x SYBR 
Premix Ex Taq II, 1 x ROX reference Dye, 0.4 µM forward and reverse primers and 50 ng 
template DNA was prepared. PCR was conducted using a QuantStudio 3 Real-Time PCR System 
(Applied Biosystems, USA) with the following conditions: initial denaturation at 95°C for 30 
seconds, followed by 40 cycles consisting of 95°C for 5 seconds, then 60°C for 30 seconds. To 
confirm that successful qPCR reactions amplified a single product, melt curves were conducted 
for each primer pair over the range 60-95°C and analysed for the presence of a single peak. 
Products were visualised by gel electrophoresis and serially diluted to generate standard 







3 Analysis of genome-wide RUNX1 localisation 
 
3.1 Introduction 
Results generated from a genome-wide approach to determining transcription factor 
localisation, together with single gene studies, as outlined in Chapter 1, suggests that the 
current understanding of RUNX1 recruitment and function at DNA is incomplete. Pairing ChIP 
assays with sequencing technology provides a snapshot of the genomic localisation of a 
transcription factor within a cell at a particular time. One such ChIP-Seq study of Runx1 binding 
in murine embryonic stem cells identified its consensus sequence TG(T/C)GGT in only just over 
half of all Runx1-bound regions, suggesting that binding in the remaining regions may be due 
to either novel consensus sequences or recruitment by other factors (Tanaka, Joshi et al. 
2012). A novel sequence was proposed, which comprises a longer consensus sequence and 
contains a TGTAGT motif in the 3’ region. This sequence is only a single base mismatch to the 
canonical RUNX1 consensus sequence and was found to be enriched in Runx1-bound regions 
that did not contain the canonical consensus sequence. However, binding through this variant 
sequence still only accounts for a small proportion of the binding within these regions. 
 
A gene-specific investigation of RUNX1 regulation of the gene encoding the integrin β4 
reinforces this finding. Reporter studies of the ITGB4 gene indicate that the gene is regulated 
by RUNX1 and sequential deletion constructs of the ITGB4 promoter and subsequent 
reductions in responsiveness narrow the responsive region to between 175 and 58 bp 
upstream from the TSS (Phillips, Taberlay et al. 2018). Though this region contains putative 
RUNX1 consensus sequences, deletion and mutation of these sequences had no effect on 
responsiveness, indicating that regulation of the ITGB4 gene is not dependent on consensus 




Two ChIP-seq databases have recently been compiled which describe RUNX1 binding in 
Kasumi-1 cells. Kasumi-1 cells are a leukaemic cell line which expresses both RUNX1 and the 
fusion protein RUNX1-ETO. Firstly, a study by Trombly et al. examined the co-localisation of 
RUNX1 and the fusion protein RUNX1-ETO with the nuclear co-repressor protein (N-CoR) and 
co-activator p300 (Trombly, Whitfield et al. 2015). This study also generated ChIP-Seq libraries 
for histone modifications H3K4me3 and H3K27me3, associated with gene activation and 
repression, respectively. Secondly, a study by Ptasinska et al. investigated the dynamics of 
RUNX1/RUNX1-ETO regulation, demonstrating that the two complexes compete for the same 
genomic sites (Ptasinska, Assi et al. 2014). Additionally, this study determined the response of 
the transcriptional regulatory system after knock-down of RUNX1 or RUNX1-ETO, leading to 
impairment of cellular viability and loss of self-renewal respectively. While both of these 
studies generated whole-genome localisation data for RUNX1 and RUNX1-ETO, neither 
examined the genomic context of either in any great detail. Nor did they investigate the 
mechanisms of recruitment of the transcription factor to regulatory regions, beyond 
identifying that RUNX1 and RUNX1-ETO bound regions display enrichment of consensus 
sequences. Of relevance, ChIP-seq studies conducted in mouse cells found that only a minority 
of RUNX1 binding occurred in promoter regions, with the rest located largely in intergenic and 
intronic regions (Tanaka, Joshi et al. 2012, Zang, Luyten et al. 2016).  
 
The model of RUNX1 gene regulation in which it recognises and binds canonical TG(T/C)GGT 
consensus sequences in the promoter regions of its target genes therefore does not fully 
describe the genome-wide localisation of RUNX1, leading to the hypothesis that alternative 
mechanisms are responsible for RUNX1 binding outside of promoter regions and in the 
absence of its consensus sequence. Herein, the genomic and sequence context of RUNX1 and 
48 
 
RUNX1-ETO binding has been examined within a publicly available ChIP-seq dataset with the 
aim of characterising atypical RUNX1 binding events and using results from this analysis to 




3.2.1 Genome-wide analysis of RUNX1 ChIP-Seq data 
Publicly available data from the human RUNX1 ChIP-seq study conducted by Trombly et al., 
including called ChIP peaks, was accessed from the Gene Expression Omnibus (Trombly, 
Whitfield et al. 2015; GSE62847). The RUNX1 and RUNX1-ETO peaks from a second study 
(Ptasinska, Assi et al. 2014; GSE29225) were used for confirmation and cross-referencing. Both 
studies were conducted in the Kasumi-1 cell line, using different antibodies, but both 
recognising the RUNX1 C-terminal domain, which is not shared by RUNX1-ETO. To detect 
RUNX1-ETO, an N-terminal antibody was used, which would also be expected to bind to the 
wild-type ETO protein. 
 
3.2.1.1 Genomic context of RUNX1 binding 
The ChIP peaks from the Trombly dataset were annotated to the hg19 reference genome using 
HOMER (Heinz, Benner et al. 2010, http://homer.ucsd.edu/homer/index.html), which 
determines the centre of each peak and provides information about the surrounding genomic 
context. Each peak was defined by a 100 bp region centred on the middle of the ChIP peak and 
assigned a unique identifier. The genomic context was also determined by HOMER, using the 
default classification cut-off points and a hierarchical system in case of multiple applicable 
region classifications. Regions were designated transcription start sites (TSS, redefined as 
“promoter” in this data, if located from -1 kb to +100 bp of a TSS), transcription termination 
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site (TTS, from -100 bp to +1 kb of the end of a gene), exonic, 5’ or 3’ UTR, non-coding, intronic 
or intergenic. HOMER uses the RefSeq database to determine the distance from the centre of 
the peak to the nearest TSS. The nearest gene was identified and gene identifiers from 
Unigene, RefSeq and Ensembl databases were retrieved. Available data on gene type (i.e. 
protein coding, non-coding RNA, etc.) and a brief description of the gene according to RefSeq 
were also recorded.  
 
Analysis of the genomic context of RUNX1 binding in the dataset (Trombly, Whitfield et al. 
2015) is depicted in Figure 3.1a and revealed that the majority of RUNX1 binding occurred in 
intronic (4513 sites, 38.6%) or intergenic (3989 sites, 34.1%) regions. Promoter binding was the 
next most common, with 2511 sites (21.5%). Other annotated regions; TTS, 5’ and 3’UTRs, 
exons, and non-coding regions, accounted for only a small proportion of all binding (Figure 
3.1a). This mirrors what was described in previous studies of Runx1 binding and genomic 
localisation in mouse megakaryocytes and haematopoietic precursor cells, which reported only 
5-12% binding in promoter regions, with intergenic and intronic regions making up 49-50% and 
37-44% respectively (Wilson, Foster et al. 2010, Zang, Luyten et al. 2016). Distribution of 
genomic context for the RUNX1-ETO ChIP peaks was similar overall (Figure 3.1b), with 7109 
intronic (41.4%), 5860 intergenic (34.2%) and 2859 promoter (17.5%) peaks with relatively 
little binding in other regions. This was as expected, as a 71% overlap between RUNX1 and 
RUNX1-ETO ChIP peaks was previously reported from this dataset (Trombly, Whitfield et al. 







Figure 3.1. Genomic distribution of RUNX1 and RUNX1-ETO ChIP binding in Kasumi-1 cells. 
Number of ChIP peaks in each genomic region as categorised by HOMER analysis of data from 
Trombly, Whitfield et al., 2015 et. al for A) RUNX1 or B) RUNX1-ETO is shown.  
  

























































































3.2.1.2 Presence of consensus sequences at RUNX1 binding sites 
Using HOMER’s known motif function, each peak was assessed for the presence of any of four 
RUNX family consensus sequences, plus an ETS:RUNX hybrid sequence, within 500 base pairs 
up or down stream (Heinz, Benner et al. 2010). HOMER’s known motif function uses sequences 
experimentally determined from previous studies (Barski, Jothi et al. 2009, Hollenhorst, 
Chandler et al. 2009, Wilson, Foster et al. 2010, Little, Noushmehr et al. 2011, Sanda, Lawton 
et al. 2012) (Table 3.1). A peak with at least one of these sequences present within this 
window was classified as “consensus present” and a peak with no consensus sequences within 
500 bp was classified as “consensus absent”. “Consensus present” peaks accounted for the 
majority of identified RUNX1 (79.8%) and RUNX1-ETO (75%) binding (Figures 3.2a, 3.2b). 
However, “consensus absent” ChIP peaks accounted for 1 in 5 binding sites for RUNX1 and 1 in 





Table 3.1. RUNX Consensus Sequences. 
Position weight matrices used by HOMER motif analysis to determine presence or absence of 
consensus sequences in the ChIP dataset generated by Trombly, Whitfield, et al., 2015. Motifs 
were determined from previous experimental studies (Barski et al., 2009; Hollenhorst et al., 











Figure 3.2. Presence of RUNX consensus sequences at ChIP peaks. 
Number of ChIP peaks within the Trombly dataset (Trombly, Whitfield et al. 2015) with or 














































To determine if peaks occurring in the absence of a consensus sequence are distributed 
consistently throughout the genome, the genomic context of the “consensus present” and 
“consensus absent” peaks was determined. Considered as a percentage of total number of 
RUNX1 ChIP peaks occurring in each genomic region, a consensus sequence was associated 
with the majority (81-88%) of peaks identified in intergenic regions, introns, exons, non-coding 
regions and 3’ UTR (Figure 3.3a), comparable to the genome-wide average of 79.8% (Figure 
3.2a). However, peaks annotated to TTS, 5’ UTRs, and promoter regions had a comparatively 
higher proportion of peaks found to lack a consensus sequence (26%, 35% and 44% 
respectively; Figure 3.3a). There is therefore a disparity in localisation of “consensus absent” 
RUNX1 ChIP peaks. When all peaks are considered, RUNX1 binding is most commonly 
distributed in intergenic and intronic regions with about 20% at promoter regions (Figure 
3.4a). This distribution is similar if only the “consensus present” peaks are considered (Figure 
3.4b). In contrast, in promoter regions 1080 peaks were identified that were not associated 
with a consensus sequence (Figure 3.4c), almost twice as many as observed for any other 









Figure 3.3. Presence of RUNX1 consensus sequence associated with a ChIP peak by genomic 
region.  
Number of ChIP peaks with or without a RUNX consensus sequence within 1000 bp (±500 bp) 
per genomic region as determined by HOMER for A) RUNX1 or B) RUNX1-ETO.  
 
  



























































































The similarity in genomic distribution of RUNX1-ETO to RUNX1 peaks also held for the 
presence of consensus sequences within these peaks (Figures 3.3b, 3.5a and 3.5b). However, 
the RUNX1-ETO peaks that were not associated with a consensus sequence show a slightly 
different distribution pattern to RUNX1 (Figure 3.5c) as while promoter regions have a 
comparably higher percentage of peaks lacking a consensus sequence (almost 50%), 
localisation to promoters make up only approximately one third of total RUNX1-ETO binding in 
the absence of a consensus sequence (Figure 3.5c) compared to nearly half for RUNX1 (Figure 
3.4c). This reflects higher numbers of RUNX1-ETO ChIP peaks within intergenic and intronic 
regions that did not contain consensus sequences compared to RUNX1, with approximately 
20% of the RUNX1-ETO peaks in these regions lacking consensus sequences. Despite this, 
RUNX1-ETO binding shows a similar enrichment of “consensus absent” binding in promoter 
regions and 5’ UTRs (46% and 41%, respectively) though the increase in TTS regions is not 
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Figure 3.4. The genomic distribution of RUNX1 ChIP peaks categorised by presence of a 
consensus sequence.  
Breakdown of genomic context as determined by HOMER annotation of A) all RUNX1 ChIP 
peaks B) ChIP peaks containing consensus sequences and C) ChIP peaks in which a consensus 
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Figure 3.5. The genomic distribution of RUNX1-ETO ChIP peaks categorised by presence of a 
consensus sequence. 
Breakdown of genomic context as determined by HOMER annotation of A) all RUNX1-ETO ChIP 
peaks B) ChIP peaks containing consensus sequences and C) ChIP peaks in which a consensus 




To summarise, promoter regions comprise only a relatively small proportion of RUNX1 and 
RUNX1-ETO occupancy, with the majority of localisation occurring in intergenic or intronic 
regions. Additionally, RUNX1 and RUNX1-ETO ChIP peaks have been identified in the absence 
of recognised RUNX consensus sequences across the genome, but the proportion of ChIP 
peaks which are not associated with a consensus sequence is higher in promoters than other 
regions, accounting for almost half of observed promoter RUNX1 ChIP peaks. 
 
3.2.1.3 Epigenetic context of RUNX1 binding 
The epigenetic environment of a DNA locus influences the ability and mechanism by which 
transcription factors interact with the genome. In particular, CpG dinucleotides are susceptible 
to epigenetic modification by methylation, which can lead to transcriptional silencing when 
accumulation of this modification occurs in CpG islands in gene promoters (Jones 2012). 
Therefore, the GC context of RUNX1 ChIP peaks in promoter regions was considered in order 
to assess the potential impact of DNA methylation on the regulation of RUNX1 target genes. 
Specifically, the CpG context of each promoter ChIP peak was analysed using HOMER to 
determine percentages of CpG sites and GC content. The percentage of CpG sites ranged from 
0 to 18% for annotated ChIP peaks, meaning that for each 100 bp region up to 9 out of 50 
dinucleotides were CpGs. Interestingly, a clear trend emerged for both RUNX1 and RUNX1-ETO 
ChIP peaks in which higher CpG percentages were observed for peaks without consensus 
sequences than for those in which consensus sequences were present (Figure 3.6). This trend 
was likewise evident in the GC% of the ChIP peak regions, calculated from the number of 
guanine and cytosine residues in the 1000 bp surrounding the centre of the ChIP peak, which 
ranged from 25 to 82% GC content with higher percentages apparent for “consensus absent” 
peaks (Figure 3.7). This potentially demonstrates a preference for RUNX1 recruitment to CpG 







Figure 3.6. Percentage CpG content categorised by presence of consensus sequence. 
Proportion of consensus present or absent A) RUNX1 and B) RUNX1-ETO promoter ChIP peaks 
separated by percentage of CpG sites in the 100 bp region surrounding each peak (to the 
nearest 0.01%).  
  



























Figure 3.7. Percentage GC content categorised by presence of consensus sequence.  
Proportion of consensus present or absent A) RUNX1 and B) RUNX1-ETO ChIP peaks separated 














































3.2.1.4 Co-localisation of RUNX1 with co-factors 
Information on co-factor binding, specifically p300 and N-CoR (nuclear receptor corepressor), 
was also available from ChIP-seq data generated by Trombly and colleagues (Trombly, 
Whitfield et al. 2015). These factors were chosen in the original study as they are known to 
interact with RUNX1 and RUNX1-ETO respectively. p300 is typically associated with gene 
activation and interacts with numerous nuclear proteins as a coactivator (Eckner, Ewen et al. 
1994). Conversely, N-CoR is a repressive cofactor which facilitates a reduction in target gene 
expression (Hörlein, Näär et al. 1995).  Distance to the nearest co-factor ChIP peak was 
determined for RUNX1 and RUNX1-ETO peaks in intronic, intergenic and promoter regions, as 
these represent the majority of the dataset. The distance from the RUNX1 peak was arbitrarily 
categorised as <500 bp, <10,000 bp, intervals of 10,000 bp up to 50,000 bp, and >50,000 bp. 
For RUNX1/RUNX1-ETO ChIP peaks within intergenic and intronic regions, the nearest p300 
peak was most commonly located either within 500 base pairs or further than 50,000 bp, with 
more distant peaks more prevalent (Figure 3.8). For RUNX1/RUNX1-ETO ChIP peaks in 
promoter regions the nearest p300 peak was more frequently within 500 base pairs, which is 
to be expected as p300 itself tends to localise to promoters, as well as active enhancers 
(Holmqvist and Mannervik 2013). For both RUNX1 and RUNX1-ETO ChIP peaks, an enrichment 
for p300 peaks within 500 base pairs was observed for peaks that did not contain a consensus 
sequence, compared to peaks where a consensus sequence was present. This was apparent 










Figure 3.8. Distance to the nearest p300 ChIP peak by genomic context of RUNX1 peak.  
Number of RUNX1 intergenic, intronic and promoter ChIP peaks categorised by the distance to 
the nearest p300 ChIP peak for A) all peaks, B) ChIP peaks containing consensus sequences, 
and C) ChIP peaks in which a consensus sequence was not identified.  

























































































Figure 3.9. Distance to the nearest p300 ChIP peak by genomic context of RUNX1-ETO peak.  
Number of RUNX1-ETO intergenic, intronic and promoter ChIP peaks categorised by the 
distance to the nearest p300 ChIP peak for A) all peaks, B) ChIP peaks containing consensus 
sequences, and C) ChIP peaks in which a consensus sequence was not identified.  






















































































N-CoR peaks were located within 500 base pairs of the RUNX1 or RUNX1-ETO ChIP peak in 
more than half of all intergenic and intronic cases and in almost half of promoter cases (Figures 
3.10a, 3.11a). The pattern of binding of N-CoR relative to RUNX1 / RUNX1-ETO is similar when 
only “consensus present” or “consensus absent” peaks are considered (Figures 3.10b-c, 3.11b-
c), indicating that N-CoR localisation was not influenced by whether RUNX1 or RUNX1-ETO was 
recruited in the presence or absence of consensus sequences. This analysis demonstrates an 
increased localisation of p300, but not N-CoR in the vicinity of RUNX1 and RUNX1-ETO when 
they are bound in the absence of a consensus sequence, which may imply a functional 











Figure 3.10. Distance to the nearest N-CoR ChIP peak by genomic context of RUNX1 peak. 
Number of RUNX1 intergenic, intronic and promoter ChIP peaks categorised by the distance to 
the nearest N-CoR ChIP peak for A) all peaks, B) ChIP peaks containing consensus sequences, 
and C) ChIP peaks in which a consensus sequence was not identified.  























































































Figure 3.11. Distance to the nearest N-CoR ChIP peak by genomic context of RUNX1-ETO 
peak. 
 Number of RUNX1-ETO intergenic, intronic and promoter ChIP peaks categorised by the 
distance to the nearest N-CoR ChIP peak for A) all peaks, B) ChIP peaks containing consensus 
sequences, and C) ChIP peaks in which a consensus sequence was not identified.  






















































































3.2.2 Analysis of RUNX1 binding at promoter regions 
3.2.2.1  Identification of alternative consensus sequences for RUNX1 recruitment 
As RUNX1 binding in the absence of a recognised consensus sequence is more common in 
gene promoters than other regions of the genome, this subset of RUNX1 ChIP peaks was 
selected for further investigation in order to understand the mechanism of RUNX1 recruitment 
in the absence of consensus sequence binding. Approximately 50% of promoter RUNX1 peaks 
were not associated with a RUNX consensus sequence, and therefore HOMER was used to 
identify any common sequence in these promoters that may be responsible for RUNX1 
recruitment. The genomic positions of each “consensus absent” promoter peak were compiled 
and entered into the HOMER findMotifsGenome.pl program (Heinz, Benner et al. 2010, 
http://homer.ucsd.edu/homer/index.html). Both known and de novo motifs enriched in 
regions in the input file were identified. The top eleven results by p-value for known motifs 
were variations of the ETS consensus sequence, followed by the E-box sequence (Table 3.2). 
The most significant result, the FLI-1 (ETS) motif was identified at the location of 48.15% of this 
subset of promoter RUNX1 ChIP peaks, compared to only 15.48% of assessed background 
regions, which were randomly selected regions matched on GC content. Interestingly ETS 
family members are well described as binding partners for RUNX1, and a RUNX1 complex 
containing FLI-1 was identified through a similar analysis of murine Runx1 (Wilson, Foster et al. 
2010). De novo motif discovery characterised 17 enriched motifs not specifically associated 
with particular transcription factors (Table 3.3). The most significant of these was a sequence 
similar to the EHS ETS consensus sequence, which was identified in 48% of “consensus absent” 
promoter regions (compared to 14.5% of background sequences). Interestingly, sequences 
similar to RUNX2 and RUNX consensus binding sequences were identified in 24% and 18% of 
analysed regions respectively. This indicates that some of the promoters categorised as 
“consensus absent” may in fact be recruiting RUNX1 through non-canonical variant consensus 
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Table 3.2. Motifs enriched in RUNX1 “consensus absent” promoter ChIP peaks as determined 
by Homer motif analysis. 
Images of the 20 most significantly enriched sequences within 200 bp of promoter RUNX1 ChIP 
peaks that do not contain canonical RUNX1 consensus sequences. The motif image indicates 
the proportion of each nucleotide at a given position by relative size. The name and type of 
each motif is drawn from Homer databases. The percentage of target sequences with each 






Table 3.3. Homer de novo motifs enriched in RUNX1 “consensus absent” promoter ChIP 
peaks. 
Images of sequences enriched in promoter RUNX1 ChIP peaks that do not contain canonical 
RUNX1 consensus sequences, which do not correspond to known transcription factor 
consensus sequences. The motif image indicates the proportion of each nucleotide at a given 
position by relative size. The most similar transcription factor sequence in the Homer database 
is identified. The percentage of target sequences with each motif is listed, as well as the 





3.2.2.2 Biological pathways enriched for RUNX1-bound promoters 
To determine whether the two categories of RUNX1 binding (i.e. in the presence or absence of 
a consensus sequence) were responsible for regulating functionally distinct genes and 
biological processes, the biological networks and processes these genes are involved in were 
investigated. The nearest gene for each promoter peak in the two categories were determined 
and Ingenuity Pathway Analysis (IPA) was used to perform a core analysis. Analysis was 
conducted using the flexible format and genes identified through human gene symbols in 
association with the HUGO Gene Nomenclature Committee (HGNC) and Entrez Gene 
guidelines, to identify the biological pathways enriched for RUNX1 bound genes.  
 
The most significant biological pathway for both sets of genes was EIF2 signalling, which 
contained 28 genes with RUNX1 promoter binding in the presence of a consensus sequence 
and 25 without consensus sequences (Table 3.4). This pathway is involved in stress response, 
reducing global translation and allowing cells to conserve resources or, alternatively, inducing 
apoptosis (Wek, Jiang et al. 2006). Other highly enriched pathways include phagosome 




Table 3.4. Biological pathways enriched for genes under both RUNX1 binding modalities. 
Pathways highly enriched for genes exhibiting both RUNX1 binding modalities as determined 
by IPA analysis. The number of genes with RUNX1 promoter ChIP peaks in each pathway was 







Interestingly, a third of all enriched pathways contained only one category of genes, indicating 
that there are biological pathways containing genes with promoters comprising RUNX1 ChIP 
peaks that fell within only the “consensus present” or “consensus absent” category. A 
proportion of these would occur by chance, and these are likely to be those smaller pathways 
containing only one or two RUNX1 bound genes. However, a number of pathways contained 
upwards of ten RUNX1 bound genes, which is perhaps indicative of likely functionally distinct 
RUNX1 activity within these pathways. A functional distinction in RUNX1 binding modality 
between different pathways raises the possibility of a broader and more flexible role for 
RUNX1 in regulating target genes. Different binding mechanisms could potentially respond 
differently to RUNX1 modulation and to its disruption in diseases such as leukaemia.  
 
To further investigate potential functional distinctions between RUNX1 binding modalities, a 
filtering process was developed to rank biological pathways of interest. The IPA analysis 
generates a P-value for each pathway identified, indicating the enrichment of RUNX1 bound 
genes in the pathway above what is predicted to occur by chance. Pathways were ranked by P-
value and the top 100 pathways considered for further analysis. These top 100 pathways were 
categorised as containing genes identified as “consensus present”, “consensus absent” or 
both. Pathways identified as being enriched for genes with only one binding modality were 
considered further (Table 3.5). Pathways containing fewer than ten RUNX1 bound genes were 
excluded on the basis that these are more likely to contain genes from only one binding 
category purely by chance, thus selecting only those which may represent functionally distinct 




Table 3.5. Biological pathways enriched for genes with RUNX1 promoter ChIP peaks. 
Pathways containing genes exhibiting only one RUNX1 binding modality from the top 100 
significant pathways enriched for RUNX1-bound genes as determined by IPA analysis. The 





This filtering strategy enabled the identification of pathways of potential biological interest as 
well as groups of genes that may be instructive in characterising the different modalities of 
RUNX1 recruitment. For example, the Aryl hydrocarbon receptor and HMGB1 signalling 
pathways, (Figures 3.12, 3.13) contained genes with promoters that bound RUNX1, but in the 
absence of consensus sequences. In addition, some of these genes were focused to nodes 
within the pathway. Similarly, the RhoA and HIPPO signalling pathways (Figures 3.14, 3.15), 





Figure 3.12. Diagram of the Aryl Hydrocarbon Signalling Pathway.  
Map of protein interactions contributing to Aryl Hydrocarbon signalling generated by IPA. All identified RUNX1-bound promoters of genes within this 
pathway lacked consensus sequences. Pathway elements with RUNX1 promoter ChIP peaks are highlighted in pink. Double outlines around highlighted 
nodes indicate that a number of genes contribute to that portion of the pathway, at least one of which contains a promoter RUNX1 ChIP peak. Pathway 
element shapes represent functional classes of gene products; rectangles with solid lines for cytokines, rectangles with dotted lines for growth factors, 




Figure 3.13. Diagram of the HMGB1 Signalling Pathway.  
Map of protein interactions contributing to HMGB1 signalling generated by IPA. All identified 
RUNX1-bound promoters of genes within this pathway lacked consensus sequences. Pathway 
elements with RUNX1 promoter ChIP peaks are highlighted in pink. Double outlines around 
highlighted nodes indicate that a number of genes contribute to that portion of the pathway, 
at least one of which contains a promoter RUNX1 ChIP peak. Pathway element shapes 
represent functional classes of gene products; rectangles with solid lines for cytokines, 
rectangles with dotted lines for growth factors, triangles for phosphatases, diamonds for 






Figure 3.14. Diagram of the RhoA Signalling Pathway.  
Map of protein interactions contributing to RhoA signalling generated by IPA. All identified 
RUNX1-bound promoters of genes within this pathway contained consensus sequences. 
Pathway elements with RUNX1 promoter ChIP peaks are highlighted in pink. Double outlines 
around highlighted nodes indicate that a number of genes contribute to that portion of the 
pathway, at least one of which contains a promoter RUNX1 ChIP peak. Pathway element 
shapes represent functional classes of gene products; rectangles with solid lines for cytokines, 
rectangles with dotted lines for growth factors, triangles for phosphatases, diamonds for 






Figure 3.15. Diagram of the HIPPO Signalling Pathway.  
Map of protein interactions contributing to HIPPO signalling generated by IPA. All identified 
RUNX1-bound promoters of genes within this pathway contained consensus sequences. 
Pathway elements with RUNX1 promoter ChIP peaks are highlighted in pink. Double outlines 
around highlighted nodes indicate that a number of genes contribute to that portion of the 
pathway, at least one of which contains a promoter RUNX1 ChIP peak. Pathway element 
shapes represent functional classes of gene products; rectangles with solid lines for cytokines, 
rectangles with dotted lines for growth factors, triangles for phosphatases, diamonds for 







The classical model of transcription factor binding describes the transcription factor being 
recruited by a consensus sequence at promoter elements and affecting transcriptional change 
directly by recruiting co-factors and transcriptional machinery (Levine and Tjian 2003). This is 
also a model that has been well described for the RUNX1 transcription factor, for example in 
regulating M-CSF and CD36 (Zhang, Fujioka et al. 1994, Armesilla, Calvo et al. 1996). However, 
the data outlined here suggest that regulation of genes by RUNX1 is far more complex than the 
simple model of consensus sequence mediated transcription factor binding. Analysis of ChIP-
seq data challenges the idea that RUNX1 modulates transcription solely via the established 
RUNX1 binding mechanism in two main ways. Firstly, analysis of genome wide distribution of 
RUNX1 indicates that binding in promoter regions represents only a minority of RUNX1 
localisation and that binding is more prevalent in intergenic and intronic regions. Secondly, 
binding in the absence of a recognised consensus sequence is relatively common, occurring in 
1 in 5 RUNX1 binding events across the genome, and is even more prevalent in promoter 
regions (Figures 3.2, 3.3a). Taken together, this indicates that RUNX1 is binding to DNA in a 
manner which is occurring at loci outside of the expected genomic context and sequence 
specificity and suggests that additional mechanisms govern RUNX1 recruitment to DNA and 
transcriptional regulation by RUNX1. 
 
Genome-wide technologies such as ChIP-seq are increasingly uncovering this kind of 
unexpected binding behaviour of transcription factors, as the increased scope of the analysis 
generates data from regions which were not priority targets for case-by-case studies as was 
the case for Myc (Guo, Li et al. 2014). In the past, it has been difficult to gain a holistic 
understanding of transcription factor binding across the genome due to the challenge of 
identifying and functionally characterising transcription factor binding outside promoter 
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regions. This resulted in an increased focus on promoter regions, as these are the best 
understood transcription factor bound regulatory regions and the most straightforward to 
locate. The focus on promoters has potentially left other genomic regions under-investigated. 
This is particularly true for transcription factors such as RUNX1 with well-characterised 
consensus sequences. These sequences are easily identifiable bioinformatically and therefore 
have directed the selection of targets for further study. However, the specifically targeted 
nature of these studies means that while they provide the opportunity to investigate 
regulation of individual promoters in detail, they do not necessarily provide a true holistic map 
of transcription factor activity and function. 
 
Genome-wide ChIP-seq data has identified regions of DNA to which RUNX1 binds in a manner 
independent of recognised consensus sequences. It is possible that this finding has no 
functional relevance for RUNX1 and is merely an artefact of the ChIP process, the cross-linking 
of RUNX1 to DNA and subsequent immunoprecipitation a result of coincidental proximity and 
not functional binding. While possible, the similarity of results between the Trombly and 
Ptasinska datasets (Ptasinska, Assi et al. 2014, Trombly, Whitfield et al. 2015), and the 
comparability to data from mouse studies (Wilson, Foster et al. 2010, Tanaka, Joshi et al. 2012) 
indicates that the “consensus sequence absent” binding identified is not just experimental 
artefact. It is also possible that while the binding of RUNX1 to DNA observed in these studies is 
specific, RUNX1 has no function at regions where it is recruited in the absence of a consensus 
sequence. Given that protein-DNA binding is an energetically unfavourable reaction, it seems 
inefficient for this to occur without purpose and is an unlikely explanation for the 
phenomenon. If this is the case, non-functional RUNX1 binding should be identified relatively 




Localisation of RUNX1 independently of the recognised consensus sequence suggests that 
there is an additional mechanism by which RUNX1 locates its targets. There are a number of 
possibilities for recruitment mechanisms. Firstly, it is possible that RUNX1 is acting in a 
completely sequence independent manner, being recruited indiscriminately through affinity 
for DNA. However, this seems unlikely in the case of RUNX1, given the increase in non-
consensus sequence dependent binding frequency observed in promoter regions compared to 
intergenic or intronic regions. Indiscriminate binding would likely result in an even distribution 
of this type of binding throughout the genome, which is evidently not the case for RUNX1. This 
suggests that there is a secondary mechanism involved in targeting RUNX1 to the genome. 
 
It is more likely that another transcription factor is directly interacting with the DNA and that 
RUNX1 is recruited by this protein. This has been identified as the mechanism for other 
transcription factors once thought to depend on consensus sequence binding, such as Myc 
(Guo, Li et al. 2014).  A study of the Myc ChIP-seq data identified binding in the absence of the 
canonical E-box sequence (CACGTG) and demonstrated that the consensus sequence (or other 
possible 8-mers) insufficiently accounts for its genome-wide occupancy. Analysis of Myc 
localisation detected co-localisation with the transcriptional machinery itself and suggested 
that Myc recruitment in non-E-box regions was driven by interactions between the 
transcription factor and the transcriptional machinery rather than by recruitment to DNA. 
Some possible co-factors for RUNX1 have been identified in studies of transcription factor co-
localisation in haematopoietic cells, including SCL, LYL1, LMO2, GATA2, ERG, and FLI-1 (Wilson, 
Foster et al. 2010, Diffner, Beck et al. 2013). In addition to evidence that these transcription 
factors commonly occupy the same genomic positions, direct protein-protein interactions have 
been demonstrated between RUNX1 and GATA2, SCL and ERG (Wilson, Foster et al. 2010). This 
mechanism is supported by evidence of frequent ETS consensus sequences present in RUNX1-
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bound promoters which lack a canonical RUNX1 consensus sequence, particularly that of FLI1 
which is present at almost half of these sites (Figure 3.12). Data from p300 occupancy also 
supports this mechanism, with p300 binding occurring closer to RUNX1 ChIP peaks in 
promoters without consensus sequences than those with consensus sequences (Figure 3.8). 
This may suggest that RUNX1 binding in the absence of a consensus sequence is associated 
with active transcriptional complexes, including p300, and that these complexes may be 
involved in the recruitment of RUNX1. 
 
Another possible explanation for RUNX1 recruitment at promoters in the absence of a 
recognised consensus sequence is that these genes are being regulated by RUNX1 through 
distal regulatory enhancers which form long-range DNA loops to bring RUNX1 into the 
proximity of the target promoters. The ability of RUNX1 to act at enhancer elements 
containing its consensus sequence has been well described, for example in regulating the 
human granulocyte macrophage colony-stimulating factor (GM-CSF) gene (Bowers, Calero-
Nieto et al. 2010). The presence of RUNX1 at distal regulatory elements such as enhancers may 
also explain the unexpected prevalence of RUNX1 in intergenic and intronic genomic regions.  
 
Pathways enriched for genes with RUNX1 binding in their promoters provide an insight into 
the biological relevance of RUNX1 regulation. Of particular interest are the pathways which 
contain genes regulated by RUNX1 in only one of its binding modalities (“consensus present” 
or “consensus absent”). If these differential pathways represent real clustering of genes 
regulated by RUNX1 through different mechanisms, this has implications for the nature of 
RUNX1 regulatory networks. If there are two distinct regulatory mechanisms for RUNX1 which 




• What is the biological purpose of the two binding modalities? 
• Do changes in RUNX1 expression or function affect these pathways differently?  
• Are the genes in pathways where RUNX1 is recruited independently of consensus 
sequence subject to additional control mechanisms in the form of other transcription 
factors?  
 
It is known that genes regulated through the well described consensus sequence dependent 
mechanism are disrupted by expression of the fusion protein RUNX1-ETO (Lam and Zhang 
2012), which contains the same DNA binding and recognition domain as the wild type protein 
but has the transactivation domain replaced with a repressive domain. Analysis of ChIP-seq 
data demonstrates a similar binding distribution for RUNX1-ETO as for RUNX1, with binding 
occurring both largely in non-promoter regions and in contexts in which the recognised 
consensus sequence is absent. It is worth noting, however, that the antibody used to detect 
RUNX1-ETO is unable to distinguish between the RUNX1-ETO fusion protein and the wild type 
ETO protein. Little is known about the function of the ETO protein on its own, including its DNA 
binding ability, though studies indicate that it may have a role in gut development (Calabi, 
Pannell et al. 2001). As the protein is not highly expressed in haematopoietic cells, it is not 
likely to significantly confound the results of the RUNX1-ETO ChIP-seq data analysed here 
(Barseguian, Lutterbach et al. 2002), although this could partly explain the incomplete overlap 
of RUNX1 and RUNX1-ETO binding. The observed binding of RUNX1-ETO in the absence of a 
consensus sequence raises the question of whether genes regulated in this manner respond 




If individual genes are affected differently by RUNX1 disruption and these genes form parts of 
distinct biological pathways, it stands to reason that these pathways may be differently 
susceptible to dysregulation, for example during the development of cancer.  
 
Analysis of genome-wide ChIP data suggests an important role for RUNX1 at non-promoter 
regions and recruitment of the protein in the absence of a recognised consensus sequence. 
Identification of genes that fall into these categories, and furthermore, pathways over-
represented by different modalities of RUNX1 binding provides a platform to explore questions 
arising from this data. Several such pathways were identified, which provide examples of 









4 Regulation of candidate gene promoters by RUNX1 
 
4.1 Introduction 
Bioinformatic analysis of genome-wide RUNX1 localisation has highlighted its recruitment to 
DNA in the absence of canonical consensus sequences. While this occurs throughout the 
genome, it is particularly prevalent in promoter regions. ChIP-seq analysis is a useful tool for 
identifying transcription factor binding, however, the detection of a protein at a particular DNA 
locus by ChIP does not necessarily indicate that the protein has a functional effect at that 
locus. ChIP analysis usually relies on formaldehyde cross-linking of proteins and DNA. This 
method captures a snapshot of protein in the vicinity of DNA at the point of cross-linking, 
which may include proteins which have only a transient and/or non-functional interaction with 
the DNA. Normalisation against background readings and statistical analysis are employed to 
reduce detection of random binding, but the functional effect of the protein at a particular 
locus must still be experimentally confirmed.  
 
IPA analysis described in Chapter 3 identified biological pathways enriched for RUNX1 binding 
at gene promoters, and further, identified pathways in which binding was exclusively 
associated with either the presence or the absence of a recognised consensus sequence (Table 
3.4). Some of these pathways contain ‘nodes’ enriched for these different categories of genes 
which provide an ideal opportunity to explore the functional relevance of RUNX1 recruitment 
to DNA in the absence of its consensus sequence and whether the modality of binding 
influences RUNX1 function. 
 
For example, the Rho signalling pathway which regulates cell adhesion molecules as well as cell 
migration and polarity contained 16 genes which were found to bind RUNX1 in their promoters 
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in association with a RUNX1 consensus sequence (Table 3.14). Of these, 4 ARHGAP genes 
appear in a functional node consisting of 9 related genes. These genes encode Ras homology 
GTPase-activating proteins (GAPs), which are important in regulating the ratio of GTP bound to 
GDP bound RhoA, affecting its role as a molecular switch. GAPs function by acting as a catalyst 
for Rho GTPase, accelerating the hydrolysis of GTP to GDP and inactivating Rho molecules 
(Haga and Ridley 2016). The human genome contains approximately 80 GAPs, but fewer than 
half have been extensively studied. Rho GAPs have been commonly associated with restricting 
cell migration and invasion, and are frequently downregulated in cancer (Kandpal 2006). 
   
In contrast, the HMGB1 signalling pathway, which is involved in proinflammatory cytokine 
response, contained 11 genes which were found to bind RUNX1 in their promoters (Table 
3.13), however none of these promoters contained canonical RUNX1 consensus sequences. Of 
these 11 genes, 4 appeared in a functional node of 7 histone modifying genes. These genes 
encode proteins which transfer acetyl groups to lysine residues on target proteins. Acetylated 
proteins are involved in a diverse range of processes, such as cell cycle control, metabolism 
and stress response (Drazic, Myklebust et al. 2016).  
 
It is tempting to speculate that these two clusters of genes that demonstrate RUNX1 binding at 
their promoters are regulated by distinct RUNX1-dependent mechanisms, determined by 
different mechanism of recruitment, and this supports a hypothesis that RUNX1 can regulate 
gene expression in a manner that is independent of its canonical consensus sequence.  The 
aims of this chapter were therefore to explore the regulation of these two categories of 
promoters by RUNX1 and whether they respond differently to the RUNX1-ETO fusion protein, 
and further to investigate whether there are contextual or structural features that characterise 
these different sites of RUNX1 binding.  
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4.2 Results  
4.2.1 Selection of candidate genes 
Biological pathways from IPA analysis were inspected to determine the distribution of RUNX1-
bound genes within the pathway. A number of RUNX1-bound genes were identified within 
clusters of related genes at network “nodes” (Table 4.1). RUNX1 genes within these nodes 
were selected as candidates for functional studies. Specifically, the genes HAT1, KAT6A, KAT6B 
and KAT7 were selected from a cluster of histone acetyl transferase genes in the HMGB1 
signalling pathway. These 4 genes fall within a ‘node’ of 7 genes within the HMGB1 signalling 
pathway, were all found to bind RUNX1 at their promoters as determined by ChIP-seq (Chapter 
3), but in the absence of a recognised consensus sequence. Further examination of genes in 
this node identified a RUNX1-ETO binding peak in the promoter of the KAT2B gene, which was 
therefore also included as a candidate for functional analysis. In contrast, ARHGAP 1, 4, 9, and 
12 are part of a 9 gene ‘node’ within the RhoA signalling pathway, all genes contain RUNX1 




Table 4.1. Genes clustered within RHOGAP and HAT nodes of the RhoA and HMGB1 
signalling pathways. 
Genes identified by IPA analysis as having RUNX1 ChIP peaks in their promoter regions, as well 
as genes without peaks from the same node within the pathway. Genes with RUNX1 ChIP 
peaks were selected as candidate genes for further analysis. *RUNX1 binding was not 







4.2.2 Analysis of candidate promoters which bind RUNX1 in the presence of a 
consensus sequence 
To determine whether the selected ARHGAP family genes are expressed in haematopoietic 
cells and therefore whether RUNX1 is likely to contribute to their regulation in these cells, their 
expression in the leukaemic cell lines K562, KG1a, and Kasumi-1 was assessed. These three cell 
lines are derived from leukaemic cells and represent different stages of leukaemogenesis (see 
Chapter 2.1). mRNA was extracted from each cell line, analysed by RT-qPCR, and expression of 
each gene normalised to GAPDH expression. Expression of the RhoA signalling pathway genes, 
ARHGAP1, ARHGAP4, ARHGAP9 and ARHGAP12 was examined. All genes were detected in all 
cell lines (Figure 4.1), however, there was variation in the expression levels between cell lines. 
For each gene, expression tended to be lowest in K562, with higher expression in Kasumi-1 and 
KG1a cells, although for ARHGAP1 this difference was not significant for Kasumi-1 cells. Mean 
relative expression of ARHGAP4 in K562 cells was approximately a third of that observed in 
KG1a and Kasumi-1 cells, although this difference was not significant. Expression of ARHGAP 1, 
4, and 12 were similar in KG1a and Kasumi-1 cells, while ARHGAP9 expression was significantly 





Figure 4.1. Expression of candidate ARHGAP family genes in leukaemic cell lines.  
Total mRNA was isolated from K562, KG1a and Kasumi cells, reverse transcribed and 
expression levels of candidate genes (as noted) determined by qRT-PCR, normalised to GAPDH. 
Values are expressed as mean ±SEM (n=3). Statistical significance was determined by one-way 




To validate the selected candidate genes as functional RUNX1 targets, luciferase reporter 
constructs were generated incorporating their promoter regions. Constructs comprising a 
region of approximately 500-800 bp upstream of the TSS, as necessary to include the site to 
which the RUNX1 ChIP peak was mapped, were generated using the pXPG luciferase reporter 
plasmid (Figure 4.2). For ARHGAP1, ARHGAP4 and ARHGAP 12, a RUNX1 ChIP peak was present 
in both sets of ChIP-seq data (Ptasinska, Assi et al. 2014, Trombly, Whitfield et al. 2015). In 
addition, RUNX1-ETO binding was detected to these promoters (Trombly, Whitfield et al. 
2015). In contrast the ARHGAP9 ChIP peak was not replicated in the Ptasinska dataset 
(Ptasinska, Assi et al. 2014) and on further analysis the associated consensus sequence was 
located downstream of the TSS and this gene was therefore not included in the promoter 
analysis.  
 
Activity of the ARHGAP1, ARHGAP4, and ARHGAP12 promoter constructs was assessed 
following their transfection into K562 cells. Basal activity of all promoters was detected in K562 
cells (Figure 4.3a). Following overexpression of RUNX1, increased activity of between 5 and 7-
fold compared to CMV control transfected cells was observed for the ARHGAP4 and 
ARHGAP12 promoters (Figure 4.3b). In contrast, no change in ARHGAP1 promoter activity was 





Figure 4.2. Promoter constructs generated from genes with RUNX1 ChIP peaks associated 
with a consensus sequence.  
Schematic representation of candidate gene promoter regions analysed in reporter assays. 
RUNX1 ChIP peaks from Trombly, Whitfield et al. (2015) are represented by grey bars. ChIP 
peaks replicated in data from Ptasinska, Assi et al. (2014) are marked by †, sites of RUNX1-ETO 
ChIP peaks from Trombly, Whitfield et al. (2015) are marked by *. RUNX1 consensus sequences 
are represented by red bars (details in Table 4.2). Scale indicates distance in base pairs from 
the TSS, represented by arrows. Regions were amplified by PCR and ligated into the pXPG 








Figure 4.3. Consensus sequence present candidate promoter response to RUNX1 
overexpression.  
K562 cells were transfected with promoter-pXPG constructs as well as a RUNX1 expression or 
CMV control vector. Protein was harvested 24 hours post-transfection and luciferase activity 
was measured. Values are expressed as mean values ±SEM (n=3-4) of: A) raw luminescence 
values for CMV and RUNX1 transfections, as indicated and B) luminescence of RUNX1 
overexpression transfections relative to CMV. Statistical analysis was conducted using 























In conclusion, the promoter regions of ARHGAP4 and ARHGAP12 respond as expected for a 
classical RUNX1 target gene, with a promoter containing a recognised RUNX1 consensus 
sequence, but the ARHGAP1 promoter does not respond directly to RUNX1 overexpression in 
K562 cells. The consensus sequences identified in these promoters were therefore examined 
(Table 4.2) to determine whether differences in these sequences may explain their disparate 
responses to RUNX1. Interestingly, despite containing two ETS:RUNX consensus sequences, to 
which the observed ChIP peak was mapped (identical to those in the ARHGAP4 promoter) and 
a third more distal RUNX canonical consensus sequence (similar to that in ARGHAP12), the 
ARHGAP1 promoter was not responsive to RUNX1. This suggests that the RUNX1 consensus 
sequence alone is not sufficient to support activation of a promoter by RUNX1 in a reporter 




Table 4.2. Consensus sequences present in candidate promoter regions.  
DNA sequences containing RUNX consensus sequences within candidate promoters. 
Consensus sequence types obtained from HOMER (http://homer.ucsd.edu/homer/). Core 






4.2.3 Analysis of candidate promoters which recruit RUNX1 in the absence of a 
consensus sequence 
The HMGB1 pathway candidate genes, HAT1, KAT6A, KAT6B, KAT7 and KAT2B, represent a 
functional cluster of genes and that all had RUNX1 binding detected at their promoters in the 
absence of a consensus sequence. Expression of all genes was detected by RT-qPCR in all three 
myeloid cell lines, K562, KG1a and Kasumi-1, although the pattern of expression was different 
for each gene (Figure 4.4). HAT1 expression was significantly lower in KG1a cells compared to 
both K562 and Kasumi-1 cells. Conversely, KAT6A displayed significantly higher expression in 
KG1a cells than in either of the other cell lines. KAT6B exhibited low expression in K562 and 
KG1a cells, but significantly higher Kasumi-1 expression. Both KAT7 and KAT2B showed 
comparable expression across all three cell lines assayed. Notably, the expression of KAT6A 
and KAT6B across all cell lines was lower than that of other HAT genes by a factor of 5-10. In 
conclusion, all candidate genes were expressed in the haemopoietic cell lines, but their 
expression was variable across cell lines. While the HMGB1 genes were generally more highly 
expressed than the RhoA pathway genes the pattern of expression for individual genes was not 





Figure 4.4. Expression of candidate HAT family genes in leukaemic cell lines.  
Total mRNA was isolated from K562, KG1a and Kasumi cells, reverse transcribed and 
expression levels of candidate genes (as noted) determined by qRT-PCR normalised to GAPDH. 
Values are expressed as mean ±SEM (n=3). Statistical significance was determined by one-way 




Luciferase reporter constructs comprising a region of approximately 500-1000 bp upstream of 
the TSS of the HMGB1 signalling pathway gene promoters, including the region to which the 
RUNX1 ChIP peak was mapped, were generated using the pXPG luciferase reporter plasmid 
(Figure 4.5). For HAT1, KAT6A, KAT6B and KAT7 the RUNX1 ChIP peak was present in both sets 
of ChIP-seq data (Ptasinska, Assi et al. 2014, Trombly, Whitfield et al. 2015). The KAT2B RUNX1 
ChIP peak was only detected in the Ptasinska data set (Ptasinska, Assi et al. 2014). RUNX1-ETO 
peaks were also mapped to the HAT1, KAT6B and KAT2B regions. The KAT7 promoter 
contained two RUNX1 ChIP peaks, one near the TSS and another approximately 550 bp 
upstream. A RUNX1-ETO peak was also detected at the KAT7 promoter, but only at the site of 
the distal RUNX1 ChIP peak.  
 
Activity of the gene promoters was then assayed following transfection of the promoter 
constructs into K562 cells, with basal luciferase activity detected for all promoters, although 
the levels were relatively low for both KAT6A and KAT2B (Figure 4.6a). The response of the 
promoters following RUNX1 overexpression was variable (Figure 4.6b). Both the KAT6B and 
KAT2B promoters responded to RUNX1 with an approximately 3-fold increase in promoter 
activity. This demonstrates responsiveness of both these promoters to RUNX1 in the absence 
of a canonical consensus sequence and supports the hypothesis that RUNX1 binding at these 
promoters has a functional outcome. In contrast, HAT1 and KAT6A promoter constructs did 
not respond to RUNX1 overexpression, despite the ChIP evidence of RUNX1 localisation at 
these promoters. This suggests that for these promoters, RUNX1 cannot bind and/or 
transcriptionally regulate the promoter in a reporter context or that RUNX1 binding alone is 
not sufficient to regulate these genes. Distinct from both of these responses, the construct 
containing the region -764 to +37 bp of the KAT7 promoter showed decreased activity in 
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response to RUNX1, although this result was not significant and was likely impacted by the 





Figure 4.5. Consensus sequence absent promoter constructs.  
Schematic representation of candidate gene promoter regions analysed in reporter assays. 
RUNX1 ChIP peaks from Trombly, Whitfield et al. (2015) are represented by grey bars. ChIP 
peaks replicated in data from Ptasinska, Assi et al. (2014) are marked by †, sites of RUNX1-ETO 
ChIP peaks from Trombly, Whitfield et al (2015) are marked by *. RUNX1 consensus sequences 
are represented by red bars. Scale indicates distance in base pairs from the TSS, represented 









Figure 4.6. Consensus sequence absent candidate promoter response to RUNX1 
overexpression.  
K562 cells were transfected with promoter-pXPG constructs as well as a RUNX1 expression or 
CMV control vector. Protein was harvested 24 hours post-transfection and luciferase activity 
was measured. Values are expressed as mean values ±SEM (n=3-4) of: A) raw luminescence 
values for CMV and RUNX1 transfections and B) luminescence of RUNX1 overexpression 
transfections relative to control. Statistical analysis was conducted using Student’s two-tailed 
t-test with paired values. *p<0.05. 
  
  



















The KAT7 promoter construct encompassed two identified RUNX1 ChIP peaks, a distal site at -
675 to -575 bp and a proximal site at-109 to -9 bp, with the distal site containing a RUNX1 
consensus sequence. To determine the precise region responsible for transcriptional 
repression in response to RUNX1, analysis of a deletion construct lacking the region from -764 
to -530 bp and removing the distal RUNX1 ChIP site was generated. This deletion relieved the 
repressive effect of RUNX1, with RUNX1 overexpression having no effect on the deletion 
construct, indicating that the repressive effect of RUNX1 was due to the distal site containing 
the consensus sequence (Figure 4.7). To further investigate RUNX1 function at this site, the 
distal region (-764 to -530 bp) was cloned upstream of the HAT1 promoter in the HAT1-pXPG 
plasmid. To test the potential of this element to act as an enhancer, it was inserted in both 
forward and reverse orientation adjacent to the HAT1 promoter. A characteristic of enhancers 
is that they are able to function in either direction due to the flexibility of chromatin loops 
(Zentner and Scacheri 2012). The resulting constructs were transfected into K562 cells 
alongside the HAT1 promoter construct alone. Results show increased expression for the 
KAT7-HAT1 construct in both orientations, though the forward oriented construct was more 
variable (Figure 4.8). While this contrasts with the original repressive function observed of this 
element in combination with the KAT7 promoter (Figure 4.6), it suggests that this element is 
acting as a transcriptional enhancer. The disparity in activity when this element is linked to its 
cognate promoter compared to HAT1, suggests that while this region is responsive to RUNX1, 
the nature of this response is variable. It is possible that inserting this small DNA fragment into 
an artificial construct divorces it from the broader genomic context which determines its 





Figure 4.7. KAT7 construct response to RUNX1 overexpression.  
K562 cells were transfected with KAT7 promoter-pXPG constructs with and without the distal 
ChIP site, as well as a RUNX1 expression or CMV control vector. Protein was harvested 24 
hours post-transfection and luciferase activity was measured. Values are expressed as mean 
values ±SEM (n=4) of luminescence of RUNX1 overexpression transfections relative to control. 
Statistical analysis was conducted using Student’s two-tailed t-test with paired values. No 




















Figure 4.8. KAT7-HAT1 construct response to RUNX1 overexpression.  
K562 cells were transfected with KAT7 distal site-HAT1 promoter constructs in the forward and 
reverse orientation, as well as a RUNX1 expression or CMV control vector. Protein was 
harvested 24 hours post-transfection and luciferase activity was measured. Values are 
expressed as mean values ±SEM (n=4) of luminescence of RUNX1 overexpression transfections 
relative to control. Statistical analysis was conducted using one-way ANOVA with Tukey’s 























These experiments have therefore demonstrated that RUNX1 can function as a transcriptional 
regulator at a target gene promoter in the absence of a consensus binding sequence, as 
demonstrated by the KAT6B and KAT2B promoters. However, in other instances while RUNX1 
binding was demonstrated by ChIP, RUNX1 could not regulate these promoters in isolation, as 
found for HAT1 and KAT6A. The mechanisms involved in both cases warrant further 
investigation.  
 
4.2.4 Response of candidate gene promoters to RUNX1-ETO 
In addition to binding RUNX1, the majority of candidate gene promoters examined also bound 
RUNX1-ETO (Figures 4.2 and 4.5), as determined by largely overlapping RUNX1-ETO ChIP peaks 
with the RUNX1 peaks. RUNX1-ETO is generally repressive of genes that are activated by 
RUNX1 and has been reported to compete with RUNX1 for DNA binding (Lam and Zhang 2012). 
To investigate whether promoters that respond to RUNX1 in the absence of a consensus 
sequence are similarly affected by the RUNX1-ETO fusion protein, candidates which both have 
RUNX1-ETO ChIP peaks in their promoters and show response to RUNX1 on its own (KAT2B 
and KAT6B) were co-transfected with combinations of CMV control, RUNX1 and RUNX1-ETO 
plasmids. For comparison, the ARHGAP4 promoter which contains a consensus RUNX1 
sequence and was found to be RUNX1 responsive in reporter assays was also examined. As 
expected, the ARHGAP4 promoter was activated by RUNX1 and repressed by RUNX1-ETO 
(Figure 4.9). Furthermore, activation of the ARHGAP4 promoter by RUNX1 was inhibited by co-
transfection with RUNX1-ETO.  Activation of KAT2B and KAT6B by RUNX1 was observed as 
previously, but their response to RUNX1-ETO differed from ARHGAP4. RUNX1-ETO had no 
effect on the KAT2B and KAT6B promoters and furthermore did not inhibit RUNX1 activation of 
the promoter when co-transfected with RUNX1 (Figure 4.9). This suggests that, while the ChIP-
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seq data indicates that RUNX1-ETO can be recruited to these promoters similarly to RUNX1, it 





Figure 4.9. Candidate construct response to RUNX1-ETO overexpression.  
K562 cells were transfected with promoter-pXPG constructs, as well as combinations of 
RUNX1, RUNX1-ETO and CMV control vector. Protein was harvested 24 hours post-transfection 
and luciferase activity was measured. Values are expressed as mean values ±SEM (n=3) of 
luminescence of RUNX1 overexpression transfections relative to control. Statistical analysis 
was conducted using one-way ANOVA with Tukey’s multiple comparisons post-test. No 






























4.2.5 FLI-1 as a regulatory partner in target gene regulation 
While RUNX1 binding was detected at the ARGHAP1 and HAT1 promoters by ChIP, these 
promoters failed to respond to RUNX1 in reporter assays. While the ARGHAP1 promoter 
contains a RUNX1 consensus sequence, the HAT1 promoter does not. In both cases it is 
therefore possible that RUNX1 recruitment to these promoters requires additional factors. 
One possible co-factor is FLI-1, which was the most significant result of HOMER known motif 
discovery in promoters which did not contain RUNX1 consensus sequences (Table 3.4) and has 
previously been shown to co-localise and interact with RUNX1 (Huang, Yu et al. 2009, Zang, 
Luyten et al. 2016). Both these candidate genes also have an E-box element in their promoter 
regions, which is the DNA sequence recognised by FLI-1 (Table 3.2, Figure 4.10a). FLI-1 
expression is also low in the K562 cell line in which the transfection experiments were 
undertaken (Shia, Okumura et al. 2012). To investigate whether FLI-1 may be required for 
regulation of these promoters by RUNX1, transfections were conducted as before with 
combinations of RUNX1, FLI-1 and CMV control plasmids with ARHGAP1 and HAT1 promoter 
reporters. The results show that while both ARHGAP1 and HAT1 reporter constructs respond 
to FLI-1, co-operation with RUNX1 was not evident (Figure 4.10b). Like RUNX1, FLI-1 is able to 
act as both an activator and repressor of transcription, depending on context (Li, Luo et al. 
2015), and for both these promoters, FLI-1 acted as a repressor. However, this result indicates 
that FLI-1 does not have a combinatorial role in regulation of these genes by RUNX1, and acts 








Figure 4.10. Candidate construct response to RUNX1 and FLI1 overexpression.  
A) Schematic of ARHGAP1 and HAT1 promoters. RUNX1 ChIP peaks are indicated in grey, RUNX 
consensus sequences in red and FLI-1 sequences (CAGGAAA) in yellow. B) K562 cells were 
transfected with promoter-pXPG constructs, as well as combinations of RUNX1, FLI1 and CMV 
control vector. Protein was harvested 24 hours post-transfection and luciferase activity was 
measured. Values are expressed as mean values ±SEM (n=3) of luminescence of RUNX1 
overexpression transfections relative to control. Statistical analysis was conducted using one-




4.2.6 Epigenetic markers at candidate promoters 
To investigate whether particular epigenetic characteristics are associated with the ability of 
RUNX1 to regulate a promoter in the presence or absence of a consensus sequence, the 
epigenetic environment of the candidate gene promoters was considered. As discussed in 
Chapter 3, there is evidence to suggest that RUNX1 binding in the absence of consensus 
sequences is associated with increased CpG content at binding sites. CpG islands were 
identified in all candidate promoters, indicating a potential for epigenetic regulation by DNA 
methylation. The presence of CpG islands does not confirm DNA methylation at these sites and 
provides no information on potential methylation patterns or differences between RUNX1 
binding modalities, which need to be determined experimentally for each cell type. 
Information on the presence of histone modifications in K562 cells was sourced from ENCODE 
(ENCODE Project Consortium 2007) and interrogated at the sites of RUNX1 ChIP peaks in 
candidate promoters. Three types of modifications were considered: mono- and tri-
methylation at lysine 4 on histone 3 (H3K4Me1 and H3K4Me3), and acetylation of lysine 27 on 
histone 3 (H3K27Ac). H3K4Me3 is generally considered a marker of transcriptionally active 
chromatin and is usually found near promoters. Monomethylation of the same lysine residue is 
often found near regulatory elements such as enhancers, while H3K27Ac marks are found in 
the same regions and indicate likely active regulatory elements. The combination of histone 
modifications at a given locus can provide information about the likely regulatory function of 
that region (Kimura 2013). All candidate ChIP peaks were located in the vicinity of K27 
acetylation, suggestive of active promoters (Figures 4.11 and 4.12) which is supported by the 
expression data (Figures 4.1 and 4.4). Given that candidate genes were selected based on the 
presence of a RUNX1 ChIP peaks in their promoter regions, it is unsurprising that K4 
trimethylation is present at the majority of candidate peaks, as this histone modification is also 
associated with active promoters. H3K4 monomethylation was largely absent from most 
candidate promoters, as expected for a marker usually associated with enhancer elements. 
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This modification was present at low levels at the ARHGAP4 promoter and the site of the distal 
KAT7 ChIP peak, suggesting that these regions may serve as enhancers. This supports the 
reporter assay results indicating that the distal KAT7 site is able to act as an enhancer element 
increasing activity of the HAT1 promoter (Figure 4.7). Importantly, the pattern of histone 
marks at candidate ChIP peaks is largely consistent with the expected function of these sites 
and does not appear to vary between promoters that contain consensus RUNX1 sequences 
and those that do not. This suggests that those histone modifications examined here are 









Figure 4.11. Histone modifications at consensus sequence present candidate RUNX1 ChIP 
sites.  
A) ARHGAP1, B) ARHGAP4 and C) ARHGAP12. Screenshots from UCSC Genome browser 
showing RUNX1 raw (Ptasinska, Assi et al. 2014) and peak called (Trombly, Whitfield et al. 
2015) ChIP peaks, TSS of candidate gene and ChIP peaks for histone modifications in K562 cells 
(Ram, Goren et al. 2011) (https://www.encodeproject.org/, GSM733656, GSM733680, 
GSM733692).   
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Figure 4.12. Histone modifications at candidate RUNX1 ChIP sites.  
A) HAT1, B) KAT6A, C) KAT6B, D) KAT7 and E) KAT2B. Screenshots from UCSC Genome browser 
showing RUNX1 raw (Ptasinska, Assi et al. 2014) and peak called (Trombly, Whitfield et al. 
2015) ChIP peaks, TSS of candidate gene and ChIP peaks for histone modifications in K562 cells 




4.2.7 Expression in epigenetically modified cells 
To determine whether modifying the epigenetic environment influences activity of the 
endogenous candidate genes where RUNX1 binds in the absence of a consensus sequence, 
K562, KG1a and Kasumi-1 cells were treated with either 5-aza-2’-deoxycytidine (decitabine), 
trichostatin A (TSA) or both and the expression of HMGB1 pathway candidate genes was 
assessed by RT-qPCR. Decitabine is an analogue of cytidine which inhibits DNA methylation by 
incorporating into DNA during division and inhibiting DNA methyltransferases (Hackanson and 
Daskalakis 2014). TSA is an inhibitor of class I and II histone deacetylase enzymes, which alters 
gene expression by preventing the removal of acetyl groups from histone tails, causing the 
decompaction of chromatin (Wood, Rymarchyk et al. 2018). The expression of HAT1, KAT6A 
and KAT6B was determined in K562, KG1a and Kasumi-1 cells (Figure 4.13). These candidates 
were selected for analysis due to the presence of a CpG island in their promoter regions and 
their relatively low baseline expression in one or all of the experimental cell lines. Low 
expression levels may result from epigenetic repression, which could be relieved by treatment 
with decitabine if they are the result of DNA methylation at the promoter CpG island or by TSA 
treatment if the cause is compaction into heterochromatin. Expression of HAT1 did not change 
following decitabine or TSA treatment in either K562 or Kasumi-1 cells, which is as expected 
given the relatively high baseline expression in these cell lines. In KG1a cells, HAT1 expression 
increased after TSA treatment compared to untreated cells but decreased in both the 
decitabine treated and combination azacytidine and TSA treated cells. KAT6A and KAT6B 
expression was similarly reduced after treatment with decitabine in both KG1a and Kasumi-1 
cells, though neither showed significant changes in K562 cells. KAT6A expression was 
unchanged by TSA treatment in all cell lines, and the combined treatment showed the same 
reduction in expression compared to untreated cells as the decitabine treatment alone. 
Treatment of KAT6B with TSA resulted in decreased expression in both KG1a and Kasumi-1 
cells, with combined TSA and decitabine treatment producing a cumulative reduction in 
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expression. These data indicate that demethylation has a negative effect on expression of 
HAT1, KAT6A and KAT6B in KG1a and Kasumi-1 cells, which runs counter to expectations, as 
CpG island methylation is generally considered a repressive modification but may be due to 










Figure 4.13. Expression of candidate genes in leukaemic cell lines treated with epigenetic 
modifiers.  
Total mRNA was isolated from K562, KG1a and Kasumi cells treated with either decitabine, 
TSA, or both, reverse transcribed and expression measured using qPCR with primers for A) 
HAT1, B) KAT6A, and C) KAT6B, then normalised to β2-microglobulin. Values are expressed as 
mean ±SEM (n=3). Statistical significance determined by one-way ANOVA with Tukey’s 




The data presented in this chapter reveal the complexity of regulation of genes by RUNX1. 
Though all candidate genes were expressed in leukaemic cell lines, their expression varied by 
cell type and the variation did not follow a consistent pattern across the candidate genes.  
 
The candidate genes ARHGAP4 and ARHGAP12 demonstrate the archetypical mechanism of 
RUNX1 gene regulation, in which RUNX1 acts on promoter regions in the vicinity of its 
consensus sequence. In contrast ARHGAP1 did not respond to RUNX1 in a reporter context, 
despite the presence of a RUNX1 consensus sequence in its promoter.  
 
The lack of response to RUNX1 observed for the ARHGAP1 promoter indicates that, in this case 
at least, the presence of a RUNX consensus sequence is not sufficient to drive transcription. It 
is possible that the lack of response is caused by variations in the consensus sequence itself. 
However, the RUNX1 ChIP peak detected at the ARHGAP1 promoter contains two copies of the 
extended ETS:RUNX sequence (Table 4.1), the major binding residues of which are identical to 
those in the ARHGAP4 promoter, which is RUNX1 responsive. This indicates that it is not the 
sequence itself preventing a RUNX1 response, and that something else is missing from the 
promoter construct. It may be that the surrounding sequence context is important for the 
RUNX1 response or that an additional co-factor is required in this instance. The ARHGAP1 
promoter construct also contained a canonical RUNX consensus sequence at the distal end of 
the cloned fragment, which is identical to the sequence found in the ARHGAP12 promoter. 
This element was also not sufficient to support a RUNX1 response in a reporter assay and no 
RUNX1 binding was detected at this site by ChIP, suggesting again that the broader context of 
the sequence is important both in a reporter assay but also in the endogenous environment, 




The candidate gene promoters KAT6B and KAT2B, which do not contain consensus sequences, 
respond directly to RUNX1 overexpression in reporter assays. This supports the hypothesis of 
this study that RUNX1 can regulate its target genes through a mechanism which does not 
require a consensus sequence. The question, then, is exactly what the mechanism is for this 
non-consensus regulation. It is possible that RUNX1 is being recruited to lower affinity DNA 
sites directly, or to a novel consensus sequence, though this does not explain the greater 
propensity of such binding observed in promoter regions compared to the rest of the genome. 
A more likely explanation is that the response is mediated by another factor such, as is 
postulated for Myc (Guo, Li et al. 2014). 
 
The activity of the KAT7 promoter is repressed by RUNX1 overexpression. The promoter region 
contains two RUNX1 ChIP peaks, one of which is associated with a consensus sequence. 
Deletion of the consensus sequence containing site largely relieved the repression, suggesting 
that this site is responsible for the observed repression and that the KAT7 promoter is 
responsive to RUNX1 in a consensus sequence-dependent manner. 
 
Despite evidence that promoters can respond directly to RUNX1 in the absence of a consensus 
sequence, not all such promoters behave the same. Candidate promoters HAT1 and KAT6A did 
not respond to RUNX1 overexpression. This lack of response may occur for the same reasons 
discussed above for ARHGAP1, or it may be that the RUNX1 ChIP peak observed at these loci is 
the result of binding elsewhere that has been brought into proximity of the promoter at the 




FLI-1 is a good candidate for the ‘missing factor’ for candidate promoters not responding to 
RUNX1, as FLI-1 consensus sequences are enriched in regions of non-consensus RUNX1 ChIP 
binding. Additionally, direct interactions between RUNX1 and FLI-1 have been demonstrated in 
a haematopoietic model previously (Wilson, Foster et al. 2010). It is possible that the FLI-1 
consensus sequence is responsible for directing FLI-1 to its targets where it subsequently 
recruits RUNX1 to affect transcription. However, this hypothesis was not supported by the 
evidence from co-transfection assays of RUNX1 and FLI-1. The HAT1 and ARHGAP1 promoters 
were both repressed by overexpression of FLI-1, and this was unaffected by the presence of 
RUNX1, indicating that there is no combinatorial effect of RUNX1 and FLI-1 regulation on these 
promoters. In order to identify potential co-regulators, co-transfections could be conducted 
using a high-throughput method to test a wider range of transcription factors. Alternatively, a 
“pull-down assay” could be conducted using the promoter region as bait and paired with mass 
spectrometry to identify other factors bound at these promoters to narrow down the focus for 
functional studies.  
 
RUNX1 disruption is a common occurrence in the development of haematological malignancies 
such as leukaemia. Therefore, the question of whether genes in which RUNX1 binds in the 
absence of a consensus sequence respond in the same manner as those with consensus 
sequences to this disruption was investigated. The translocation resulting in the fusion protein 
RUNX1-ETO is one of the most common and well-studied disruptions and therefore a suitable 
starting point to investigate non-consensus binding in disrupted systems. RUNX1-ETO contains 
the DNA binding domain but lacks the transactivation domain of wild-type RUNX1 and is 
therefore localises to RUNX1 targets by binding to the RUNX1 consensus sequence (Lam and 
Zhang 2012). Additionally, RUNX1-ETO recruits co-repressive factors such as N-CoR and 
therefore represses genes which are normally activated by RUNX1 (Lin, Mulloy et al. 2017). 
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RUNX1 and RUNX1-ETO compete for binding sites in heterozygotes, resulting in impaired 
activation by RUNX1 combined with repression by RUNX1-ETO (Lam and Zhang 2012). 
Combinatorial transfection assays demonstrated this dominant negative effect of RUNX1-ETO 
on RUNX1 at the ARHGAP4 promoter, which is behaving as an archetypical RUNX1 target. The 
promoter was activated by RUNX1 and repressed by RUNX1-ETO, with RUNX1-ETO repressing 
activation of the ARGHAP4 promoter by RUNX1. In contrast, the candidate promoters that did 
not contain RUNX1 consensus sequences, KAT6B and KAT2B, did not respond to RUNX1-ETO. 
Further, RUNX1-ETO had no effect on activation of the promoters by RUNX1 overexpression. 
This is interesting, as it demonstrates a difference in the ability of RUNX1-ETO to disrupt 
RUNX1 function depending on the mechanism by which RUNX1 is regulating its target genes. 
RUNX1-ETO has been demonstrated to bind to each of these promoters in ChIP-seq 
experiments, so the difference in response appears to be one of regulation rather than 
recruitment (Trombly, Whitfield et al. 2015). As the DBD is identical between RUNX1 and 
RUNX1-ETO, it is clear that this difference occurs in the replaced transactivation domain. It is 
possible that this domain is somehow required for RUNX1 to regulate targets in the absence of 
a consensus sequence, potentially through interactions with other co-factors. 
 
The histone context of candidate genes in K562 cells is consistent with their roles as active 
promoters, which is supported by the presence of p300 at all promoter sites. The reduction in 
expression of candidate HATs after treatment with decitabine is unusual, in that removal of 
DNA methylation is generally considered an activating modification (Estey 2013). It is possible 
that due to the role these genes play in regulating epigenetic processes, specifically histone 
acetylation, they are subject to the interplay of multiple epigenetic mechanisms rather than 
just methylation. Results from Chapter 3 indicate that RUNX1 binding in the absence of 
consensus sequences is associated with higher levels of both G and C nucleotides and CpG 
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dinucleotides. However, the two categories of candidate promoters were similar in terms of 
both GC% and CpG%. GC% ranged from 44-72% for “consensus absent” promoters and 57-72% 
for “consensus present” promoters. Consensus sequence absent CpG% ranged from 1.1-8.8%, 
while consensus sequence present promoters ranged from 1.2-12.3%. In both cases, no 
candidate was at either extreme of the range described in the genome-wide data (Figures 3.6 
and 3.7).   
 
Biological pathways have been identified that could be key targets of RUNX1, and which may 
be regulated by RUNX1 through mechanistically distinct means. Elements of these pathways 
with RUNX1 binding in their promoters are biologically relevant in the development of AML. 
Repression of KAT7 in AML patients reduces acetylation of histone 4 at lysine 5 and is 
associated with poorer patient outcomes (Sauer, Arteaga et al. 2015). Both KAT6A and KAT6B 
have been identified as targets of chromosomal fusions and rearrangements in leukaemia 
(Liang, Prouty et al. 1998, Chaffanet, Gressin et al. 2000, Panagopoulos, Fioretos et al. 2001). 
Disruption of RUNX1 therefore has the potential to result in not only dysregulation of its direct 








5 Potential role of enhancers in RUNX1 gene regulation 
5.1 Introduction 
While much of the functional analysis of RUNX1 has focused on its association with promoters, 
the majority of RUNX1 binding, as determined through ChIP-seq analysis and described in 
Chapter 3, occurs in either intergenic or intronic regions. The functional outcome of RUNX1 
binding in these regions is likely more complex than at promoter regions, but it is an obvious 
possibility that the transcription factor is binding to these regions because they serve as 
transcriptional enhancers. Enhancers are regulatory regions which facilitate transcription of 
their associated genes (Schoenfelder and Fraser 2019), and while the mechanisms through 
which they regulate gene expression are relatively well understood identifying and 
demonstrating the functionality of enhancer regions is a challenging endeavour, for several 
reasons. They can be located a great distance from the transcription start sites of the genes 
that they regulate and can be either upstream or downstream of the target gene. 
Furthermore, enhancers do not necessarily regulate the next closest promoter, a promoter can 
be regulated by multiple enhancers and a single enhancer can regulate multiple promoters 
(Mohrs, Blankespoor et al. 2001). No general sequence characteristic has been described that 
distinguishes enhancers, which limits the usefulness of bioinformatic tools in their 
identification and analysis. Additionally, the dynamic nature of enhancers means that 
interactions can be transient, and also cell type specific. 
 
To affect transcription at distant promoters, enhancers need to be brought into close 
proximity to their targets. For regions where the chromatin between the enhancer and 
promoter is highly compacted, the distance between regulatory regions can be small enough 
for diffusion of factors from enhancer to promoter to affect transcription. Diffusion directed by 
proteins scanning the intervening chromatin between enhancer and promoter has been 
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described at both the lac repressor in E. coli. and for eukaryotic genes, such as binding of 
C/EBP, HNF-1, and HNF-3 at the upstream enhancer of HNF-4α (Hatzis and Talianidis 2002, 
Hammar, Leroy et al. 2012).  
 
Diffusion is only a plausible mechanism for enhancer action when the distances involved are 
very small (200-400 nm) (Pennacchio, Bickmore et al. 2013). For enhancers located a greater 
distance from their targets, proximity is achieved through the formation of chromatin loops 
which serve to deliver proteins bound to DNA at the enhancer to the target promoter (Figure 
5.1a). Enhancer loops are generally confined within regions of interacting DNA bounded by 
insulator proteins called topologically associated domains (TADs, Figure 5.1b). TAD boundaries 
are conserved between different cell types, though the enhancer-promoter interactions within 
a TAD may vary greatly (Dixon, Selvaraj et al. 2012). However, as with many mechanisms of 
epigenetic regulation, TADs can be disrupted in cancer. The formation of new, smaller TADs 
interrupts normal enhancer-promoter interactions and leads to further dysregulation of genes 
(Achinger-Kawecka, Taberlay et al. 2016). This form of transcriptional disruption is particular to 
gene regulation by enhancers, as transcription factors in gene promoters are already in close 





Figure 5.1. Formation of enhancer-promoter loops.  
A) Chromatin loop formation brings enhancer elements into contact with their associated 
promoters to drive transcription. B) The presence of insulator elements interferes with this 
interaction either by interposing between the enhancer and promoter elements or by forming 





A variety of techniques have been developed to investigate the linkage between enhancers 
and their associated promoters (Han, Zhang et al. 2018). These techniques commonly involve 
identifying interacting regions by cross-linking chromatin and analysing regions of DNA which 
have been linked together. One such method is chromatin interaction analysis with paired-end 
tag (ChIA-PET) sequencing. Similar to ChIP, ChIA-PET involves cross-linking DNA and proteins, 
followed by chromatin fragmentation and immunoprecipitation of specific proteins, commonly 
transcription factors. Interacting DNA is tagged, ligated and sequenced to detect separate 
fragments bound to the same protein molecule. This is an effective method for identifying 
interacting DNA loci, with the caveat that detection relies on the presence of the chosen 
protein at the site of interaction (Fullwood, Liu et al. 2009). Other methods which do not have 
this limitation include chromatin conformation capture (3C) and its derivatives, 4C, 5C, Hi-C, 
and others, which directly investigate cross-linked chromatin (Han, Zhang et al. 2018). 
 
RUNX1, as a transcription factor, has the capacity to regulate gene transcription through 
localisation to enhancer DNA, and this has been previously described in a number of single 
gene studies. In particular, it has been shown to bind to overlapping RUNX1 consensus 
sequences as a dimer to act on an enhancer of the GM-CSF gene (Bowers, Calero-Nieto et al. 
2010) and to co-localise with transcription factor Ets1 to regulate the TRCα enhancer 
(Kasahara, Shiina et al. 2017). Genome-wide ChIP-seq analysis has shown that the majority of 
RUNX1 binding occurs outside of promoter regions (Chapter 3), leading to the hypothesis that 
this represents RUNX1 binding at enhancers which form long range DNA loops and functional 
interactions with the promoter of target genes. This scenario could also explain the lack of 
response of some candidate gene promoters to RUNX1 in reporter assays, despite 
demonstration of RUNX1 recruitment in ChIP-seq analysis (Chapter 4). While it is possible that 
such gene promoters may require additional factors not provided within the context of a 
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reporter assay, an alternative possibility is that the RUNX1 binding observed at the promoter in 
ChIP-seq analysis may be the result of direct binding at a distal regulatory region which has 
been cross-linked to the promoter due to proximity during the assay. Therefore, the potential 
for DNA loop formation between regions of RUNX1-bound DNA was investigated here.  
Interactions between intergenic/intronic RUNX1 ChIP peaks and promoter peaks were mapped 
through ChIA-PET linkage. 
 
5.2 Results 
5.2.1 Identification of RUNX1 associated enhancer-promoter pairs 
To address this, several different approaches were used to identify potential RUNX1-bound 
enhancers and their likely target promoter. Initially, a “top down” approach was used, starting 
with the entirety of intergenic and intronic RUNX1 binding observed through ChIP-seq to 
identify those likely to represent potential enhancers. Firstly, the genes with intergenic or 
intronic ChIP peaks annotated to them were considered. While all RUNX1 ChIP peaks were 
annotated to the nearest gene (Chapter 3), this does not necessarily indicate that this is the 
gene that is being regulated by RUNX1 in each instance. In fact it is estimated that only 7% of 
enhancers control the nearest gene promoter (Snetkova and Skok 2018). However, this was 
used as a starting point for interrogating the data for potential enhancers. Therefore, the ChIP-
Seq data was searched for genes with at least two separate RUNX1 peaks annotated to them: 
one in a promoter region and one in intergenic or intronic regions. This provided a subset of 





Annotation of intergenic/intronic and promoter ChIP peaks to the nearest gene produced 5515 
and 2461 unique genes, respectively. Of these 635 genes were common between the two sets, 
having RUNX1 ChIP peaks annotated to both their promoter and nearby intergenic or intronic 
regions (Table 5.1). Genes identified in this manner were then examined in the UCSC genome 
browser for interactions through interrogation of publicly available RNA Pol II ChIA-PET data 
for K562 cells, the rationale being that this ChIP-PET data set will contain regions of DNA that 
interact with RNA PolII bound promoters, at least in this cell line. Promoters containing RUNX1 
ChIP peaks were thus examined for evidence of interaction with distal regions also containing 
RUNX1 peaks using RNA Poll II ChIA-PET data (Fullwood, Han et al. 2010). In some cases, this 
identified an interaction with an intergenic or intronic peak originally annotated to the same 
gene. In others, the interaction identified was to another region containing a more distal ChIP 
peak. In both cases, the linked RUNX1 bound loci were further evaluated to determine their 
likelihood of functioning as enhancers. A particular combination of histone modifications, 
specifically the presence of monomethylation of histone 3 lysine 4 (H3K4Me1) and acetylation 
of lysine 27 (H3K27Ac), coupled with the absence of trimethylation at lysine 4 (H3K4Me3) is 
considered characteristic of an active enhancer (Bulger and Groudine 2011). Using pooled data 
from the ENCODE project from various cell types, including K562 (ENCODE Project Consortium 
2007), linked distal regions were evaluated for the presence of these histone modifications and 
genes with potential RUNX1-bound enhancers were thus identified (Table 5.1). Of the 635 
genes initially annotated to both promoter and intergenic/intronic regions, 96 were linked 
through ChIA-PET data and a further 37 of these had linked regions which displayed chromatin 
features characteristic of enhancers. Notably, the candidate genes ARHGAP1, HAT1 and KAT6B 





Table 5.1. Genes with promoter and intergenic/intronic RUNX1 ChIP peaks. 
List of genes with RUNX1 ChIP peaks in their promoters and nearby intergenic or intronic 
regions. Genes with links through ChIA-PET data from their promoter peak to another ChIP 
peak are in bold, genes where the linked peak has the histone marks associated with an 






While this method identified a set of potential enhancer linkages, it is time consuming and 
dependent on annotations to the nearest gene and therefore prone to excluding enhancers 
which operate on more distal genes. Therefore, an alternate method was used in parallel to 
bioinformatically identify promoter-enhancer pairs in the entire dataset in an unbiased 
manner. This method considered all intergenic/intronic RUNX1 peaks and linked them to the 
transcription start sites of RUNX1 promoter bound genes through the same ChIA-PET dataset 
used previously (Fullwood, Han et al. 2010). This analysis identified approximately 35,000 links 
between RUNX1 ChIP-Seq peaks, which were annotated to 9953 unique genes. Of the 635 
genes with potential enhancers identified in the previous analysis, 404 were also identified 
using this method. Additional information was gathered on the linkage, including the 
chromatin state of the linked peak (as annotated by HOMER, described in Chapter 3), the score 
of the ChIA-PET linkage, which is a measure of confidence in the relevance of the detected 
interaction, and the presence of a recognised RUNX consensus sequence at either end. This 
dataset was then filtered to only include peaks identified as being in either weak or strong 
enhancer regions according to chromatin state. Circos plots were generated from the filtered 
data for each chromosome using the RCircos package in R (Zhang, Meltzer et al. 2013) to 
visualise enhancer-TSS links. An example Circos plot for chromosome 2 is depicted in Figure 
5.2. The majority of the linkages identified occur over short distances, however some long-
distance interactions were also identified. As enhancer linkage is uncommon between 
Topologically Associated Domains (TADs), the chromatin structure around these linkages 
requires further examination, as demonstration of interactions occurring within TADs would 





Figure 5.2. Representative map of RUNX1 promoter-intergenic/intronic ChIP-PET linkages.  
Generated using the Rcircos package in R. The plot shows, from outside to inside, a map of 
Chromosome 2, names of identified linking genes and RUNX1 binding sites. The central area of 
the plot shows links between RUNX1-bound promoters and RUNX1-bound intergenic loci 
considered likely to be enhancers. Links represent regions of DNA which interact in the cell 
through RNA Polymerase II, as determined by ChIA-PET assay (Fullwood, Liu et al. 2009). Line 
colour corresponds to the presence of RUNX1 consensus sequences at the interacting sites: 
orange represents present-present interactions, red represents absent-absent and blue 




5.2.2 Analysis of candidate promoter-enhance interactions 
Bioinformatic analysis of publicly available datasets was therefore utilised to map intergenic or 
intronic RUNX1 ChIP peaks to their potential target promoters, but their function as enhancers 
and their ability to regulate the linked promoters remains to be tested. This analysis was 
therefore applied to the candidate RUNX1-bound promoters examined earlier. Of these genes, 
ARHGAP1, ARHGAP9 ARHGAP12, HAT1, and KAT6B were identified as genes with annotated 
promoter and intergenic/intronic ChIP peaks, and ARHGAP1, ARHGAP9, HAT1, KAT6B, KAT7, 
and KAT2B were included in the genome-wide ChIA-PET interaction database. Interestingly, 
despite being identified as RUNX1-bound promoters through ChIP-seq analysis (Chapter 3), 
both the ARHGAP1 and HAT1 promoters were found to be unresponsive to RUNX1 in reporter 
assays (Chapter 4). 
 
Candidate gene promoters were inspected for strong ChIA-PET links (those with a score of 10 
or above) between the RUNX1 ChIP peak site and distal regions. These distal regions were of 
particular interest if they contained another RUNX1 ChIP peak, with or without a consensus 
sequence, or were classified as an enhancer in the Functional Annotation of the Mammalian 
Genome 5 (FANTOM5) database, which comprises a map of transcription start sites and active 
enhancers derived from cap analysis of gene expression (CAGE) with single-molecule 
sequencing experimental data (Andersson, Gebhard et al. 2014). This analysis identified a 
number of potentially relevant chromatin interactions for candidate promoters (Figures 5.3 
and 5.4). Interestingly, more interactions were identified for the set of promoters which bound 
RUNX1 in the absence of a recognised consensus sequence, which could be evidence that, 
RUNX1 binding at promoters in the absence of a consensus sequence is a result of indirect 
recruitment through a linked region of DNA. Of these identified interactions, those occurring in 
candidate genes which did not respond directly to RUNX1 (HAT1 and KAT6A) were prioritised 
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for further study, as this indicates that the cloned promoter fragment alone is insufficient for 








Figure 5.3. RUNX1 ChIP peaks linked to consensus sequence present promoters.  
Schematic representation of consensus sequence present candidate genes and surrounding 
DNA. Genes are marked in blue, with transcription start sites indicated by arrows. RUNX1 ChIP 
peak sites are marked in yellow and RUNX1-ETO sites in orange. Enhancers, as identified by the 
FANTOM database (Andersson, Gebhard et al. 2014) are in purple. Linked regions identified in 
ChIA-PET data are indicted by connected bars, the colour of which indicates the strength of the 
ChIA-PET evidence, black for very strong and dark grey for moderately strong evidence 









Figure 5.4. RUNX1 ChIP peaks linked to consensus sequence absent promoters.  
Schematic representation of consensus sequence present candidate genes and surrounding 
DNA. Genes are marked in blue, with transcription start sites indicated by arrows. RUNX1 ChIP 
peak sites are marked in yellow and RUNX1-ETO sites in orange. Enhancers, as identified by the 
FANTOM5 database (Andersson, Gebhard et al. 2014) are in purple. Linked regions identified in 
ChIA-PET data are indicted by connected bars, the colour of which indicates the strength of the 
ChIA-PET evidence, black for very strong and dark grey for moderately strong evidence 




Two regions linked through ChIA-PET data were identified for HAT1 (Figure 5.5a, Table 5.2), 
one approximately 31 kb upstream of the HAT1 TSS (HAT1-31k) and one 190 kb downstream 
(HAT1+190k). The -31 kb region does not have a RUNX1 peak in the Trombly dataset which 
was used for this analysis (Trombly, Whitfield et al. 2015), but review of the Ptasinska RUNX1 
ChIP-seq dataset (Ptasinska, Assi et al. 2014), revealed an uncalled potential RUNX1 ChIP peak. 
This region is also identified as an active enhancer by FANTOM5. The +190 kb region contains a 
RUNX1 ChIP peak in the Tromby dataset (Trombly, Whitfield et al. 2015) which also contains a 
recognised RUNX1 consensus sequence. One linked region was identified for KAT6A 
approximately 100 kb upstream of the TSS (KAT6A-100k, Figure 5.5b, Table 5.2). This region 
contained a RUNX1-ETO ChIP peak but not RUNX1 in the Trombly dataset (Trombly, Whitfield 
et al. 2015) and a probable uncalled RUNX1 peak in the Ptasinska data (Ptasinska, Assi et al. 
2014). Interestingly, the interacting region for KAT6A was not detected in the earlier analyses. 
This is because the linked region does not have a called RUNX1 ChIP peak and was therefore 








Figure 5.5. Features of candidate linked regions.  
Schematic representation of consensus sequence absent candidate genes A) HAT1 and B) 
KAT6A and surrounding DNA. Genes are marked in blue, with transcription start sites indicated 
by arrows. RUNX1 ChIP peak sites are marked in yellow and RUNX1-ETO sites in orange. 
Enhancers, as identified by the FANTOM database (Andersson, Gebhard et al. 2014) are in 
purple. Linked regions identified in ChIA-PET data are indicted by connected bars, the colour of 
which indicates the strength of the ChIA-PET evidence, black for very strong and dark grey for 
moderately strong evidence. Screenshots from UCSC genome browser show raw RUNX1 ChIP 
peaks in red (Ptasinska, Assi et al. 2014) and peak called sites for RUNX1 (labelled AML in 
browser), RUNX1-ETO (labelled AML_ETO), N-CoR, p300, and H3K4 methylation designated by 
black bars (Trombly, Whitfield et al. 2015) at the linked site, as well as nearby genes, RUNX 
consensus sequences and enhancer locations.  
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5.2.2.1 Epigenetic marks at selected regions 
Histone modifications in the vicinity of the interacting regions were investigated for evidence 
of enhancer activity using ENCODE data as before, specifically the presence of H3K4Me1 and 
H3K27Ac, and the absence of H3K4Me3 (Table 5.2). The HAT1-31k site is located in an intron of 
the SLC25A12 gene and has no evidence of any of the three histone modifications. The 
HAT1+190k site shows evidence of all three marks, consistent with an active regulatory region, 
but more indicative of promoter function. This would be consistent with its location adjacent 
to the DLX2 gene and it is likely that it is a promoter element involved in regulating the nearby 
DLX2 gene. The KAT6A-100k site likewise has evidence of association with all three histone 
marks and may be associated with the promoter of the AP3M2 gene, which is 350 bp away 
from the RUNX1-ETO ChIP peak. However, the activity of enhancers is cell type specific, and 
the ENCODE data is sourced from ChIP-seq studies from seven cell lines. When considering 
only histone modifications data from K562 cells, the HAT1+190k site remains unchanged, but 
the presence of all three modifications is less pronounced at the KAT6A-100k site. While this 
analysis does not provide strong support for these elements functioning as enhancers it is 




Table 5.2. Features of candidate linked regions. 
 
 
HAT1+190k HAT1-31k KAT6A-100k 
RUNX1 ChIP peak    
RUNX1-ETO ChIP 
peak 
   
Uncalled RUNX1 
ChIP peak 
   
H3K4Me1    
H3K27Ac    
H3K4Me3    
FANTOM5 
Enhancer 
   





5.2.3 Enhancer reporter assays 
Potential enhancer regions were isolated and cloned into the pXpG luciferase reporter 
plasmid, adjacent to the relevant promoter and in both forward and reverse orientation. 
Constructs were transfected into K562 cells in the presence of RUNX1 overexpression, and 
luciferase activity measured to determine whether there was any change in activity, in 
response to RUNX1, caused by the enhancer compared to the promoter construct alone. The 
KAT6A enhancer construct (in either orientation) showed no change in activity compared to 
the promoter alone, indicating that the +100 kb region is not functioning as an enhancer, at 
least in this context (Figure 5.6a). The HAT1+190 kb linked region showed increased activity in 
response to RUNX1, in the reverse direction only (Figure 5.6b). This indicates that this region 
may function as an enhancer of HAT1 expression. The +190 kb region contains a canonical 
RUNX consensus sequence, so its response to RUNX1 may be expected, though epigenetic 
marks at the locus do not clearly indicate that it is an enhancer. Further, it increased activity of 
the promoter only when it was in the reverse orientation, suggesting activity more consistent 
with a promoter element. Interestingly, this is the orientation in which this element is 
positioned adjacent to the DLX2 gene. The HAT1-31 kb region showed no significant response 
to RUNX1 in either orientation, suggesting that, as for KAT6A-100k, this region is not acting as 










Figure 5.6. Response of enhancer constructs to RUNX1.  
K562 cells were transfected with promoter-pXPG or enhancer-promoter-pXPG constructs as 
well as a RUNX1 expression or CMV control vector. Protein was harvested 24 hours post-
transfection and luciferase activity was measured. Values are expressed as mean values ±SEM 
(n=3) of luminescence of RUNX1 overexpression transfections relative to control for: A) KAT6A-
100k; B) HAT1+190k and C) HAT1-31k. Statistical analysis was conducted using one-way 
ANOVA with Tukey’s multiple comparisons post-test. A significant difference in means was 










































































































5.2.4 Validation of enhancers by chromatin conformation capture 
The region 190 kb downstream of the HAT1 promoter increased response to RUNX1 above the 
HAT1 promoter alone in vitro, suggesting that it may be able to function as an enhancer of 
HAT1 expression. This region, and the region 31 kb upstream were selected for in vivo analysis 
of enhancer-promoter linkage. The two regions that were analysed as potential enhancers of 
HAT1 were suggested to be linked to the HAT1 promoter through RNA PolII ChIA-PET data. To 
validate theses interactions in another experimental model a chromatin conformation capture 
(3C) assay was conducted. Unlike the ChIA-PET analysis, this tests DNA interactions directly 
and does not rely on the presence of a particular protein, such as RNA PolII. 3C utilises 
formaldehyde fixation to form crosslinks between nearby chromatin regions, followed by 
restriction enzyme digestion and ligation of digested ends. This method generates fragments 
of DNA consisting of two interacting regions ligated together at the restriction site. Using 
primers designed to each fragment component, the presence of specific interacting regions 
can be detected by qPCR. Primer sets were designed to interrogate regions 40 kb upstream 
and 200kb downstream of the promoter (Figure 5.7) and used to interrogate DNA fragments 
isolated from KG1a cells. This cell line was chosen to complement the data generated by ChIA-











Figure 5.7. Map of 3C primers used to analyse interaction with the HAT1 promoter.  
Schematic diagram of the regions analysed by 3C assay. Horizontal lines represent fragments 
analysed by qPCR, red bars mark the interacting regions of interest. The HAT1 TSS is marked by 




The 3C assay detected interactions between both the +190k and -31k regions and the HAT1 
promoter anchor fragment. Amplicons representing interactions with both of these regions 
were detected at higher levels than the surrounding regions, although the +190 kb region was 
not detected as strongly as the -31kb region and was not statistically significant (Figure 5.8). 
Taken together with the ChIA-PET data from K562 cells, this provides strong evidence of 
interaction between these regions. The evidence for the HAT1+190 kb region is less clear, and 
the promoter-distal region linkage is not as pronounced. While it is possible that this region 
exerts some influence on the HAT1 promoter as an enhancer, it is more probable that it 
functions as the promoter of a different gene. An additional region at approximately 100 kb 
downstream of the HAT1 promoter was identified as highly significant in this assay and may 








Figure 5.8. Regions linked to the HAT1 promoter through 3C.  
Copy numbers of regions ligated to the HAT1 promoter as a result of 3C assay as determined 
by qPCR for A) 190 kb upstream and B) 31 kb downstream of the TSS. Position of each region is 
relative to the HAT1 promoter RUNX1 ChIP peak. Values are expressed as mean ±SEM (n=3). 
Fragments assayed by qPCR are represented by grey bands and the interacting region of 
interest is represented by the red bar. Statistical analysis was conducted using one-way 





The majority of RUNX1 binding identified in Kasumi-1 cells was found within intergenic or 
intronic regions. As RUNX1 is known to regulate some genes through their enhancers, it is 
reasonable to infer that gene regulation through enhancers is the functional outcome of 
RUNX1 binding in at least some of these regions. However, it is difficult to determine which 
binding sites are functional enhancers from genomic location alone, and even more 
challenging to ascertain the gene being regulated by each site. The methods discussed above 
attempts to use publicly available experimental data to elucidate the role of these 
intergenic/intronic binding sites, firstly by starting with promoter binding sites and inspecting 
for nearby intergenic sites, and secondly by starting with the intergenic/intronic sites 
themselves and linking to promoter regions. Both methods are valuable, and the database of 
linkages provides a genome-wide set of possible RUNX1 enhancer interactions which can be 
interrogated for genes of interest.  
 
The available ChIA-PET data used in this analysis is not ideal, as the assay was conducted in 
K562 cells (granulocytic and undifferentiated) while the ChIP-seq data is from Kasumi-1 cells 
(myeloblasts which contain the t(8;21) translocation). While these cell lines are both derived 
from leukaemic cells, it is not certain that chromatin interactions observed in one cell type are 
applicable in the other. Further influencing this is the 3C assay, which was conducted in KG1a 
cells (derived from AML bone marrow) because of the baseline activity of the candidate genes. 
While it is reasonable to expect some overlap in enhancer activity between these cell lines 
given their similarity, enhancer function is highly dependent on cell type (Jin, Li et al. 2011) and 
therefore a lack of evidence of enhancer function in one cell type does not conclusively rule 




Given that a number of gene promoters had been identified in Chapter 3 as binding RUNX1 
through ChIP-seq analysis, but did not respond to RUNX1 in reporter assays, these promoters 
represented ideal candidates for analysis of potential enhancer interactions. If these genes are 
genuine RUNX1 targets and the promoter itself is not sufficient for RUNX1 response, it is 
reasonable to infer that regulation is dependent on an additional response element, such as an 
enhancer. Potential enhancer regions were identified for the HAT1 and KAT6A genes based on 
linkage through ChIA-PET data. While HAT1 was identified as a gene with a potential enhancer 
in the linkage databases, KAT6A was not. This highlights the limitations of the filtering strategy 
employed. In addition to identifying binding that may not represent functional enhancers, 
potential enhancers which do not meet the selection criteria may be missed. In this case, as 
the linked region did not contain a RUNX1 ChIP peak in the Trombly dataset (Trombly, 
Whitfield et al. 2015), it was not considered in either bioinformatic analysis. However, the lack 
of response observed in the promoter reporter assays prompted a manual search for linked 
regions. This identified a linked RUNX1-ETO ChIP peak and potential uncalled RUNX1 ChIP peak 
from the Ptasinska data (Ptasinska, Assi et al. 2014).  
 
The KAT6A-100k region did not show a response to RUNX1 in reporter assays. This suggests 
that the region is not acting as an enhancer of the KAT6A gene. It is possible, as the linked 
region identified is in the promoter of another gene (AP3M2) that this is a true enhancer 
interaction, but that the interaction goes in the opposite direction, with the KAT6A promoter 
RUNX1 site acting as an enhancer for the promoter at the other end. A reporter assay with the 





The orientation specific activity of the +190 kb region is curious, as enhancer regions should 
function irrespective of direction. The linked region is, like the KAT6A region, in the promoter 
of another gene, in this case DLX2. The orientation of the DLX2 gene is such that the reversed 
HAT1+190 kb region is essentially the DLX2 promoter region in the correct orientation for 
transcription. It is possible that the reverse direction specific activity of the cloned region is the 
result of it being a RUNX1-responsive promoter instead of an enhancer. If so, this is not a 
particularly surprising result as the region contains a RUNX1 consensus sequence and its 
regulation by RUNX1 is to be expected. The 3C assay identified some evidence of interaction 
between the HAT1 promoter ChIP peak and the HAT1+190k region, though it was not the 
strongest interaction. The assay indicated another potential linked region at approximately 
105 kb downstream on the HAT1 TSS. This interaction was not detected in ChIA-PET linkage 
and the linked region falls within the first intron of the METAP1D gene. There is some evidence 
of H3K4Me1 marks in K562 cells at this locus, suggesting that it may have an active regulatory 
role, though the nearest RUNX1 ChIP peak is 20 kb away at the METAP1D promoter. 
 
While the evidence is not particularly strong, there is some indication that the HAT1-31k 
region is acting as a RUNX1-responsive enhancer of the HAT1 gene. This illustrates a model of 
RUNX1 activity which involves binding at distal regulatory elements which interact with gene 
promoters in the absence of consensus sequences at either site. Having demonstrated the 
feasibility of this type of RUNX1 interaction, the question of the mechanism occurring in these 
cases remains.  
 
Promoter-promoter interactions, such as those observed for HAT1 and KAT6A, have been 
observed in approximately 42% of genome-wide ChIA-PET links (Li, Ruan et al. 2012). These 
interactions have been proposed to be a result of the formation of multi-gene complexes 
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associated with the transcription machinery. It is further suggested that these promoters may 
have regulatory function on other linked promoters, acting as both promoters and enhancers 
simultaneously. This kind of chromatin interaction may account for a proportion of the 
observed RUNX1 binding in the absence of consensus sequences for ChIP-seq data. RUNX1 
recruited to a promoter in a consensus sequence-dependent manner may be detected at other 
promoter sequences through cross-linking assays if these promoters are components of the 







6 Final discussion and future directions 
 
The precise maintenance of complex regulatory networks is essential for regular cellular 
functions such as development and differentiation. The systems by which regulatory 
instructions are encoded and subsequently read by transcription factors are therefore a major 
focus for research. These systems are intricate intersections of many processes which must be 
both tightly controlled and highly responsive to changes in the cellular environment. It is 
therefore not straightforward to decipher their mechanisms of action. As new techniques to 
interrogate regulatory networks and study transcription factor function on a genome-wide 
scale are developed, our ability to understand the complex interaction between transcription 
factors and their targets, and therefore the cellular processes that they regulate, improves. 
 
RUNX1 is a master regulator of haematopoiesis, and a frequent target for mutations and 
translocations in leukaemia. A complete understanding of the mechanisms of RUNX1 action is 
necessary in order to fully comprehend its effects on regulatory networks and the impact of its 
disruption. The mechanism of RUNX1 action has always been understood in the context of its 
consensus sequence, which acts as both a marker for the transcription factor’s intended 
targets and the site of protein-DNA binding. However, evidence has emerged from both single 
gene and genome-wide studies which indicates that this view of RUNX1 action is incomplete. 
Recent studies of other transcription factors have brought into question the paradigm of 
transcription factors operating exclusively through interaction with specific DNA consensus 
sequences. 
 
One of the first and best described transcription factors to be implicated in binding in the 
absence of consensus sequences, Myc, was shown to have better genome-wide occupancy 
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correlation with transcription start sites, and therefore the transcriptional machinery, than its 
canonical E-box consensus sequences (Guo, Li et al. 2014). DNA sequences preferentially 
bound by the MYC/MAX heterodimer were subsequently investigated through protein binding 
microarrays and electrophoretic gel shift assays for all possible hexamers (Allevato, Bolotin et 
al. 2017). At least one of the top 21 bound sequences was detected at 87% of binding sites 
genome-wide, though binding to low-affinity sites was modulated by MYC dosage. Another 
recent study into the feasibility of the two proposed mechanisms of Myc action, E-box driven 
or otherwise, used an inducible Myc model system and mathematical modelling of binding 
affinities (Lorenzin, Benary et al. 2016). The study concluded that direct DNA binding does not 
fully explain the occupancy of Myc at promoters and proposes interactions with other proteins 
such as WDR5 and transcription machinery components P-TEFb, TBP and TRRAP. 
 
The data presented here from analysis of ChIP-seq experiments in human leukaemic cell lines 
supports findings from similar studies in mouse models that question the classically held view 
of RUNX1 binding and function (Tanaka, Joshi et al. 2012). Specifically, these analyses have 
demonstrated that the majority of RUNX1 binding occurs outside of promoter regions, and 
that some of the binding occurs in the absence of canonical consensus sequences. Further 
analysis of this data has begun to build a picture of the context of RUNX1 binding events in the 
absence of consensus sequences. Firstly, these binding events occur more frequently in 
promoter regions than elsewhere in the genome (almost half in promoters compared to 21% 
genome-wide). Secondly, binding in the absence of consensus sequences is associated with a 
higher CG percentage and more CpG dinucleotides. Thirdly, binding in the absence of 
consensus sequences was more closely associated with p300 binding than RUNX1 binding in 
the presence of a consensus sequence. Finally, the binding sites are enriched for a range of 
other transcription factor consensus sequences, including many ETS family member motifs. 
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Taken together, this suggests that in the absence of consensus sequences RUNX1 is recruited 
to its targets through interaction with additional factors which accumulate in the promoter 
regions of genes and are potentially dependent on DNA methylation status and the co-factor 
p300.  
 
Genes bound by RUNX1 in different modalities were demonstrated to cluster within biological 
pathways. The prevalence of pathways containing more than 10 genes with RUNX1-bound 
promoters under only one binding modality suggests that RUNX1 may control different 
biological processes through different mechanisms. Further, it is possible that these 
mechanisms respond differently to changes in the cellular environment and allow the two 
subsets of RUNX1 targets to operate independently of each other. 
 
Analysis of candidate genes selected from these different pathways by expression, reporter, 
and linkage assays has begun to elucidate the different modalities of RUNX1 action. Data from 
this study suggests three distinct models of RUNX1 transcriptional regulation. The first of these 
is the classical RUNX1 mechanism, in which RUNX1 is recruited directly through its consensus 
sequence in gene promoters (Figure 6.1a). This is illustrated by the “consensus present” 
candidate genes ARHGAP4 and ARHGAP12, which were shown to respond to RUNX1 in 
reporter assays. This mechanism is well understood in the literature and represents the 
majority of known RUNX1 activity. Further RUNX1 activation of these genes is inhibited by the 










Figure 6.1. Models of regulation by RUNX1.  
Depiction of RUNX1 action through three mechanisms: A) directly through its consensus 
sequence; B) directly in the absence of its consensus sequence; and C) indirectly, through 
interaction with distal regulatory elements and subsequent loop formation. DNA is 
represented by blue lines wrapped around nucleosomes (blue spheres) and CpG sites are 
represented by white (unmethylated) or black (methylated) circles on the DNA. Transcription 




The second proposed model is one in which RUNX1 is recruited directly to gene promoters 
through a mechanism other than its consensus sequence (Figure 6.1b). This is illustrated by the 
case of KAT6B and KAT2B, which responded to RUNX1 in reporter assays. While data from this 
study provides evidence that RUNX1 can regulate promoter activity in the absence of its 
consensus sequence, the exact mechanism involved remains to be elucidated. This manner of 
RUNX1 binding and function has been previously described at the promoter of the ITGB4 gene, 
where it is hypothesised to bind as part of a complex of hematopoietic transcription factors 
(Phillips, Taberlay et al. 2018). It is possible that RUNX1 is able to bind directly to lower affinity 
DNA sites which do not contain consensus sequences, though in this case what is directing the 
transcription factor specifically to its targets is unclear. There is no evidence from the literature 
that RUNX1 functions in a non-specific manner, and such a scenario is not supported by the 
distribution of RUNX1 binding observed from ChIP-seq data. If the binding was occurring in a 
completely sequence-independent manner it is unlikely that the proportion of “consensus 
absent” binding would be higher in promoter regions than across the rest of the genome. This 
suggests that an alternative mechanism is driving RUNX1 recruitment in the absence of its 
consensus sequence. A likely candidate, FLI-1, was ruled out as a cooperative binding factor in 
the cases of HAT1 and ARHGAP1, as while the promoter region was responsive to FLI-1, 
combinatorial transfections showed no cumulative response for RUNX1 and FLI-1 together. 
Importantly, while RUNX1-ETO was also shown to bind to these promoters in vivo, it did not 
inhibit RUNX1 activity at these promoters. However, while some promoters without RUNX 
consensus sequences responded to RUNX1, this was not the case for all promoters 
investigated. Specifically, the HAT1 and KAT6A promoters did not respond in reporter assays. 
This suggests that direct action of RUNX1 at promoters does not account for all ChIP binding 




The third model of RUNX1 action involves direct recruitment to enhancer regions and 
subsequent interaction with promoters through chromatin proximity (Figure 6.1c). This model 
incorporates the evidence from ChIP-seq that RUNX1 binding is common at regions other than 
promoters, many of which may be serving as enhancers. This is demonstrated, to some 
degree, in the case of HAT1 for the region 31 kb upstream of the TSS through 3C analysis, 
though the region did not respond in reporter assays. This particular example does not contain 
a RUNX consensus sequence at either end of the interaction, and therefore leads to the same 
questions as the second model regarding RUNX1 recruitment to either loci. The region 190 kb 
downstream of the HAT1 promoter shows some evidence of interaction with the promoter 
from 3C data and responds to RUNX1 in reporter assays, but only in the reverse orientation. 
These results, coupled with the proximity of the interacting region to the DLX2 TSS, suggests 
that the RUNX1 ChIP site at the HAT1 promoter is involved in promoter-promoter interactions. 
Such interactions are common, and have been detected in genome-wide ChIA-PET and HiC 
studies (Li, Ruan et al. 2012, Schoenfelder, Javierre et al. 2018). Promoter-promoter 
interactions occur largely, but not exclusively, within TADs and are likely the result of 
simultaneous interactions with transcriptional machinery, forming large “transcription 
factories” driving expression of genes regulated by the same transcription factors (Li, Ruan et 
al. 2012). Like promoter-enhancer interactions, these associations are dynamic and dependent 
of cell type. Alterations in cell type can lead to loss or gain of promoter-promoter interactions, 
as demonstrated in a mouse embryonic stem cell model (Joshi, Wang et al. 2015). 
 
There are limitations on the conclusions which can be drawn regarding transcription factor 
action from reporter assays. As the region of interest is amplified and ligated into plasmid 
DNA, it becomes divorced from its original chromatin context. Therefore, while these assays 
are useful in determining if a particular region is responsive to RUNX1, a negative result does 
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not definitively rule out the region as a RUNX1 target. Indeed, as discussed previously, there is 
some evidence for the involvement of epigenetic factors such as DNA methylation in the 
mechanism of RUNX1 action in the absence of its consensus sequence.  
 
In addition to the DNA sequence of the binding site, the specific structure of the site may 
influence the specificity of transcription factor binding. Factors such as helical twist and minor 
groove width contribute to the ability of DNA binding proteins to recognise binding sites. The 
“shape motif” of binding sites is not entirely independent of DNA sequence but provide an 
extra layer of specificity. A tool has been developed to determine DNA shapes enriched at 
binding sites, which has been utilised to demonstrate that MYC-MAX heterodimer has a 
different shape preference than MAX alone (Samee, Bruneau et al. 2019).  
 
The ChIP-seq analysis conducted in this study provides a useful resource for further 
investigation of RUNX1 binding in both a non-promoter and non-consensus sequence manner. 
The difficulty comes in finding functionally relevant RUNX1 binding targets within this large 
body of data. The current study utilised a candidate gene approach to begin mining the data 
for evidence of RUNX1 functionality, which resulted in the selection of clusters of genes from 
the RhoA and HMGB1 signalling pathways. These, and other pathways which contained genes 
bound by RUNX1 exclusively in the presence or absence of consensus sequences identified in 
the analysis contain more genes than were selected for analysis here. Analysis of RUNX1 
function at these additional gene promoters would provide additional evidence of the 
conditions under which RUNX1 functions in the absence of consensus sequences. It is difficult 
with current evidence to draw strong conclusions about the necessary context for RUNX1 
binding in the three models proposed above from the few clear examples of each in the 
selected candidate genes. With more data from candidate studies, it may be possible to 
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identify commonalities between genes regulated through different modalities which drive the 
different mechanisms of RUNX1 action. Commonalities between genes regulated by RUNX1 in 
the absence of consensus sequences would provide both tools with which to interrogate the 
dataset to identify more candidates, and also insight into the mechanisms occurring. 
 
To elucidate the composition of any transcription factor complex interacting with RUNX1, pull-
down assays potentially coupled with mass spectroscopy could be used. This method has 
previously been utilised to identify proteins which interact with T-box transcription factor 18 
(TBX18) and Forkhead box M1 (FOXM1) (Xie, Jia et al. 2017, Rivera-Reyes, Kleppa et al. 2018). 
This analysis would provide an indication of other proteins which commonly interact with 
RUNX1 and could be used as a basis for investigating additional factors involved in RUNX1 
binding identified in the absence of consensus sequences. 
 
It is clear that the mechanisms by which RUNX1 regulates transcription in leukaemic cells is 
more complex than previously thought. This study has identified novel RUNX1 binding 
modalities and demonstrated their functional relevance. These findings expand our 
understanding of the role of RUNX1 in gene regulation and open new avenues of investigation 
into the transcriptional mechanisms involved in transcription factor regulation by “master 
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8 Appendix: Figure 3.12 Enlarged 
 
 
 
